



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |  |   |  |
|--|--|---|--|
| (51) International patent Classification 4:<br>C07K 13/00, A61L 27/00, C12N 15/00<br>A61K 35/32, C12P 21/02  |  | A2  | (11) International Publication Number: <b>WO 89/09787</b><br>(43) International Publication Date: 19 October 1989 (19.10.89) |
| (21) International Application Number: PCT/US89/01453<br>(22) International Filing Date: 7 April 1989 (07.04.89)<br>(30) Priority data:<br>179,406                      8 April 1988 (08.04.88)      US<br>232,630                      15 August 1988 (15.08.88)      US<br>315,342                      23 February 1989 (23.02.89)      US<br>(60) Parent Applications or Grants<br>(63) Related by Continuation<br>US                                      179,406 (CIP)<br>Filed on                              8 April 1988 (08.04.88)<br>US                                      232,630 (CIP)<br>Filed on                              15 August 1988 (15.08.88)<br>US                                      315,342 (CIP)<br>Filed on                              23 February 1989 (23.02.89)<br>(71) Applicant (for all designated States except US): CREATIVE BIOMOLECULES, INC. [US/US]; 35 South Street, Hopkinton, MA 01748 (US).<br>(72) Inventors; and<br>(75) Inventors/Applicants (for US only): KUBERASAMPATH, Thangavel [IN/US]; 6 Spring Street, Medway, MA 02053 (US). OPPERMANN, Hermann [US/US]; 25 Summer Hill Road, Medway, MA 02053 (US). RUEGER, David, C. [US/US]; |  | 150 Edgemere Road, Apt. 4, West Roxbury, MA 02132 (US). OZKAYNAK, Engin [TR/US]; 44 Purdue Drive, Milford, MA 01757 (US).<br>(74) Agent: PITCHER, Edmund, R.; Lahive & Cockfield, 60 State Street, Boston, MA 02109 (US).<br>(81) Designated States: AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CF (OAPI patent), CG (OAPI patent), CH (European patent), CM (OAPI patent), DE (European patent), DK, FI, FR (European patent), GA (OAPI patent), GB (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL (European patent), NO, RO, SD, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US.<br>Published<br>Without international search report and to be republished upon receipt of that report. |  |
| (54) Title: OSTEOGENIC DEVICES   |  |   |  |
| (57) Abstract  |  |   |  |
| Disclosed are 1) osteogenic devices comprising a matrix containing osteogenic protein and methods of inducing endochondral bone growth in mammals using the devices; 2) amino acid sequence data, amino acid composition, solubility properties, structural features, homologies and various other data characterizing osteogenic proteins, and 3) methods of producing osteogenic proteins using recombinant DNA technology.  |  |   |  |

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                              |    |  |    |                          |
|----|------------------------------|----|--|----|--------------------------|
| AT | Austria                      | FR | France                                   | ML | Mali                     |
| AU | Australia                    | GA | Gabon                                    | MR | Mauritania               |
| BB | Barbados                     | GB | United Kingdom                           | MW | Malawi                   |
| BE | Belgium                      | HU | Hungary                                  | NL | Netherlands              |
| BG | Bulgaria                     | IT | Italy                                    | NO | Norway                   |
| BJ | Benin                        | JP | Japan                                    | RO | Romania                  |
| BR | Brazil                       | KP | Democratic People's Republic<br>of Korea | SD | Sudan                    |
| CF | Central African Republic     | KR | Republic of Korea                        | SE | Sweden                   |
| CG | Congo                        | LI | Liechtenstein                            | SN | Senegal                  |
| CH | Switzerland                  | LK | Sri Lanka                                | SU | Soviet Union             |
| CM | Cameroon                     | LU | Luxembourg                               | TD | Chad                     |
| DE | Germany, Federal Republic of | MC | Monaco                                   | TG | Togo                     |
| DK | Denmark                      | MG | Madagascar                               | US | United States of America |
| FI | Finland                      |    |  |    |                          |

OSTEOGENIC DEVICES

This invention relates to osteogenic devices, to genes encoding proteins which can induce osteogenesis in mammals and methods for their production using recombinant DNA techniques, to a method of reproducibly purifying osteogenic protein from mammalian bone, and to bone and cartilage repair procedures using the osteogenic device.

Mammalian bone tissue is known to contain one or more proteinaceous materials, presumably active during growth and natural bone healing, which can induce a developmental cascade of cellular events resulting in endochondral bone formation. This active factor (or factors) has variously been referred to in the literature as bone morphogenetic or morphogenic protein, bone inductive protein, osteogenic protein, osteogenin, or osteoinductive protein.

The developmental cascade of bone differentiation consists of recruitment of mesenchymal cells, proliferation of progenitor cells, calcification of cartilage, vascular invasion, bone formation, remodeling, and finally marrow differentiation (Reddi (1981) Collagen Rel. Res. 1:209-226).

- 2 -

Though the precise mechanisms underlying these phenotypic transformations are unclear, it has been shown that the natural endochondral bone differentiation activity of bone matrix can be dissociatively extracted and reconstituted with inactive residual collagenous matrix to restore full bone induction activity (Sampath and Reddi, (1981) Proc. Natl. Acad. Sci. USA 78:7599-7603). This provides an experimental method for assaying protein extracts for their ability to induce endochondral bone in vivo.

This putative bone inductive protein has been shown to have a molecular mass of less than 50 kilodaltons (kD). Several species of mammals produce closely related protein as demonstrated by cross species implant experiments (Sampath and Reddi (1983) Proc. Natl. Acad. Sci. USA 80:6591-6595).

The potential utility of these proteins has been widely recognized. It is contemplated that the availability of the protein would revolutionize orthopedic medicine, certain types of plastic surgery, and various periodontal and craniofacial reconstructive procedures.

The observed properties of these protein fractions have induced an intense research effort in various laboratories directed to isolating and identifying the pure factor or factors responsible for osteogenic activity. The current state of the art of purification of osteogenic protein from



mammalian bone is disclosed by Sampath et al. (Proc. Natl. Acad. Sci. USA (1987) 80). Urist et al. (Proc. Soc. Exp. Biol. Med. (1984) 173:194-199) disclose a human osteogenic protein fraction which was extracted from demineralized cortical bone by means of a calcium chloride-urea inorganic-organic solvent mixture, and retrieved by differential precipitation in guanidine-hydrochloride and preparative gel electrophoresis. The authors report that the protein fraction has an amino acid composition of an acidic polypeptide and a molecular weight in a range of 17-18 kD.

Urist et al. (Proc. Natl. Acad. Sci. USA (1984) 81:371-375) disclose a bovine bone morphogenetic protein extract having the properties of an acidic polypeptide and a molecular weight of approximately 18 kD. The authors reported that the protein was present in a fraction separated by hydroxyapatite chromatography, and that it induced bone formation in mouse hindquarter muscle and bone regeneration in trephine defects in rat and dog skulls. Their method of obtaining the extract from bone results in ill-defined and impure preparations.

European Patent Application Serial No. 148,155, published October 7, 1985, purports to disclose osteogenic proteins derived from bovine, porcine, and human origin. One of the proteins, designated by the inventors as a P3 protein having a molecular weight of 22-24 kD, is said to have been

purified to an essentially homogeneous state. This material is reported to induce bone formation when implanted into animals.

International Application No. PCT/087/01537, published January 14, 1988, discloses an impure fraction from bovine bone which has bone induction qualities. The named applicants also disclose putative bone inductive factors produced by recombinant DNA techniques. Four DNA sequences were retrieved from human or bovine genomic or cDNA libraries and apparently expressed in recombinant host cells. While the applicants stated that the expressed proteins may be bone morphogenic proteins, bone induction was not demonstrated. See also Urist et al., EP 0,212,474 entitled Bone Morphogenic Agents.

Wang et al. (Proc. Nat. Acad. Sci. USA (1988) 85: 9484-9488) discloses the purification of a bovine bone morphogenetic protein from guanidine extracts of demineralized bone having cartilage and bone formation activity as a basic protein corresponding to a molecular weight of 30 kD determined from gel elution. Purification of the protein yielded proteins of 30, 18 and 16 kD which, upon separation, were inactive. In view of this result, the authors acknowledged that the exact identity of the active material had not been determined.

Wozney et al. (Science (1988) 242: 1528-1534) discloses the isolation of full-length cDNA's encoding the human equivalents of three polypeptides originally purified from bovine bone. The authors report that each of the three recombinantly expressed human proteins are independently or in combination capable of inducing cartilage formation. No evidence of bone formation is reported.

It is an object of this invention to provide osteogenic devices comprising matrices containing dispersed osteogenic protein capable of bone induction in allogenic and xenogenic implants. Another object is to provide a reproducible method of isolating osteogenic protein from mammalian bone tissue. Another object is to characterize the protein responsible for osteogenesis. Another object is to provide natural and recombinant osteogenic proteins capable of inducing endochondral bone formation in mammals, including humans. Yet another object is to provide genes encoding osteogenic proteins and methods for their production using recombinant DNA techniques. Another object is to provide methods for inducing cartilage formation.

These and other objects and features of the invention will be apparent from the description, drawings, and claims which follow.

Summary of the Invention

This invention involves osteogenic devices which, when implanted in a mammalian body, can induce at the locus of the implant the full developmental cascade of endochondral bone formation and bone marrow differentiation. Suitably modified as disclosed herein, the devices also may be used to induce cartilage formation. The devices comprise a carrier material, referred to herein as a matrix, having the characteristics disclosed below, containing dispersed osteogenic protein either in its native form as purified from natural sources or produced using recombinant DNA techniques.

Key to these developments was the successful development of a protocol which results in retrieval of active, substantially pure osteogenic protein from mammalian bone, and subsequent elucidation of amino acid sequence and structure data of native osteogenic protein. The protein has a half-maximum bone forming activity of about 0.8 to 1.0 ng per mg of implant. The protein is believed to be a dimer. It appears not to be active when reduced. Various combinations of species of the proteins may exist as heterodimers or homodimers.

The invention provides native forms of osteogenic protein, extracted from bone or produced using recombinant DNA techniques. The substantially

pure osteogenic protein may include forms having varying glycosylation patterns, varying N-termini, a family of related proteins having regions of amino acid sequence homology, and active truncated or mutated forms of native protein, no matter how derived. The naturally sourced osteogenic protein in its native form is glycosylated and has an apparent molecular weight of about 30 kD as determined by SDS-PAGE. When reduced, the 30 kD protein gives rise to two glycosylated polypeptide chains having apparent molecular weights of about 16 kD and 18 kD. In the reduced state, the 30 kD protein has no detectable osteogenic activity. The deglycosylated protein, which has osteogenic activity, has an apparent molecular weight of about 27 kD. When reduced, the 27 kD protein gives rise to the two deglycosylated polypeptides have molecular weights of about 14 kD to 16 kD.

Analysis of intact molecules and digestion fragments indicate that the native 30 kD osteogenic protein contains the following amino acid sequences (question marks indicate undetermined residues):

- (1) S-F-D-A-Y-Y-C-S-G-A-C-Q-F-P-M-P-K;
- (2) S-L-K-P-S-N-Y-A-T-I-Q-S-I-V;
- (3) A-C-C-V-P-T-E-L-S-A-I-S-M-L-Y-L-D-E-N-E-K;
- (4) M-S-S-L-S-I-L-F-F-D-E-N-K;
- (5) S-Q-E-L-Y-V-D-F-Q-R;
- (6) F-L-H-C-Q-F-S-E-R-N-S;
- (7) T-V-G-Q-L-N-E-Q-S-S-E-P-N-I-Y;

- (8) L-Y-D-P-M-V-V;
- (9) V-G-V-V-P-G-I-P-E-P-C-C-V-P-E;
- (10) V-D-F-A-D-I-G;
- (11) V-P-K-P-C-C-A-P-T;
- (12) I-N-I-A-N-Y-L;
- (13) D-N-H-V-L-T-M-F-P-I-A-I-N;
- (14) D-E-Q-T-L-K-K-A-R-R-K-Q-W-I-?-P;
- (15) D-I-G-?-S-E-W-I-I-?-P;
- (16) S-I-V-R-A-V-G-V-P-G-I-P-E-P-?-?-V;
- (17) D-?-I-V-A-P-P-Q-Y-H-A-F-Y;
- (18) D-E-N-K-N-V-V-L-K-V-Y-P-N-M-T-V-E;
- (19) S-Q-T-L-Q-F-D-E-Q-T-L-K-?-A-R-?-K-Q;
- (20) D-E-Q-T-L-K-K-A-R-R-K-Q-W-I-E-P-R-N-?-A-R-R-Y-L;
- (21) A-R-R-K-Q-W-I-E-P-R-N-?-A-?-R-Y-?-?-V-D; and
- (22) R-?-Q-W-I-E-P-?-N-?-A-?-?-Y-L-K-V-D-?-A-?-?-G.

The availability of the protein in substantially pure form, and knowledge of its amino acid sequence and other structural features, enable the identification, cloning, and expression of native genes which encode osteogenic proteins. When properly modified after translation, incorporated in a suitable matrix, and implanted as disclosed herein, these proteins are operative to induce formation of cartilage and endochondral bone.

Consensus DNA sequences designed as disclosed herein based on partial sequence data and observed homologies with regulatory proteins disclosed in the literature are useful as probes for extracting genes encoding osteogenic protein from genomic and cDNA libraries. One of the consensus

sequences has been used to isolate a heretofore unidentified genomic DNA sequence, portions of which when ligated encode a protein having a region capable of inducing endochondral bone formation. This protein, designated OP1, has an active region having the sequence set forth below.

```

      1          10          20          30          40
OP1      LYVSFR-DLGWQDWIIAPEGYAAYYCEGECAFLNS
              50          60          70
      YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
              80          90          100
      ISVLYFDDSSNVILKKYRNMVVRACGCH

```

A longer active sequence is:

```

                                          -5
                                          HQRQA
      1          10          20          30          40
OP1      CKKHELYVSFR-DLGWQDWIIAPEGYAAYYCEGECAFLNS
              50          60          70
      YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
              80          90          100
      ISVLYFDDSSNVILKKYRNMVVRACGCH

```

Fig. 1A discloses the genomic DNA sequence of OP1.

The probes have also retrieved the DNA sequences identified in PCT/087/01537, referenced above, designated therein as BMPII(b) and BMPIII. The inventors herein have discovered that certain subparts of these genomic DNAs, and BMPIIa, from the same publication, when properly assembled, encode proteins (CBMPIIa, CBMPIIb, and CBMPIII) which have true osteogenic activity, i.e., induce the full cascade of events when properly implanted in a mammal

leading to endochondral bone formation. These sequences are:

```
CBMP-2a      1      10      20      30      40
              CKRHPLYVDFS-DVGWNDWIVAPPGYHAFYCHGECPFPLAD
                  50      60      70
              HLNSTN--H-AIVQTLVNSVNS-K-IPKACCVPTLSA
                  80      90     100
              ISMLYLDENEKVVVLKNYQDMVVEGCGCR

CBMP-2b      1      10      20      30      40
              CRRHSLYVDFS-DVGWNDWIVAPPGYQAFYCHGDCPFPLAD
                  50      60      70
              HLNSTN--H-AIVQTLVNSVNS-S-IPKACCVPTLSA
                  80      90     100
              ISMLYLDEYDKVVVLKNYQEMVVEGCGCR

CBMP-3       1      10      20      30      40
              CARRYLKVDFA-DIGWSEWIISPKSFDAYYCSGACQFPMPK
                  50      60      70
              SLKPSN--H-ATIQSIVRAVGVPFGIPEPCCVPEKMSS
                  80      90     100
              LSILFFDENKNVVLKVYPNMTVESCACR
```

Thus, in view of this disclosure, skilled genetic engineers can isolate genes from cDNA or genomic libraries which encode appropriate amino acid sequences, and then can express them in various types of host cells, including both procaryotes and eucaryotes, to produce large quantities of active proteins capable of inducing bone formation in mammals including humans.



The substantially pure osteogenic proteins (i.e., naturally derived or recombinant proteins free of contaminating proteins having no osteoinductive activity) are useful in clinical applications in conjunction with a suitable delivery or support system (matrix). The matrix is made up of particles or porous materials. The pores must be of a dimension to permit progenitor cell migration and subsequent differentiation and proliferation. The particle size should be within the range of 70 - 850  $\mu\text{m}$ , preferably 70 - 420  $\mu\text{m}$ . It may be fabricated by close packing particulate material into a shape spanning the bone defect, or by otherwise structuring as desired a material that is biocompatible (non-inflammatory) and, biodegradable in vivo to serve as a "temporary scaffold" and substratum for recruitment of migratory progenitor cells, and as a base for their subsequent anchoring and proliferation. Currently preferred carriers include particulate, demineralized, guanidine extracted, species-specific (allogenic) bone, and particulate, deglycosylated (or HF treated), protein extracted, demineralized, xenogenic bone. Optionally, such xenogenic bone powder matrices also may be treated with proteases such as trypsin. Other useful matrix materials comprise collagen, homopolymers and copolymers of glycolic acid and lactic acid, hydroxyapatite, tricalcium phosphate and other calcium phosphates.

The osteogenic proteins and implantable osteogenic devices enabled and disclosed herein will permit the physician to obtain optimal predictable bone formation to correct, for example, acquired and congenital craniofacial and other skeletal or dental anomalies (Glowacki et al. (1981) Lancet 1:959-963). The devices may be used to induce local endochondral bone formation in non-union fractures as demonstrated in animal tests, and in other clinical applications including periodontal applications where bone formation is required. Another potential clinical application is in cartilage repair, for example, in the treatment of osteoarthritis.

Brief Description of the Drawing

The foregoing and other objects of this invention, the various features thereof, as well as the invention itself, may be more fully understood from the following description, when read together with the accompanying drawings, in which:

FIGURE 1A represents the nucleotide sequence of the genomic copy of osteogenic protein "OP1" gene. The unknown region between 1880 and 1920 actually represents about 1000 nucleotides;

FIGURE 1B is a representation of the hybridization of the consensus gene/probe to the osteogenic protein "OP1" gene;

FIGURE 2 is a collection of plots of protein concentration (as indicated by optical absorption) vs elution volume illustrating the results of bovine osteogenic protein (BOP) fractionation during purification on heparin-Sepharose-I; HAP-Ultragel; sieving gel (Sephacryl 300); and heparin-Sepharose-II;

FIGURE 3 is a photographic reproduction of a Coomassie blue stained SDS polyacrylamide gel of the osteogenic protein under non-reducing (A) and reducing (B) conditions;

FIGURE 4 is a photographic reproduction of a Con A blot of an SDS polyacrylamide gel showing the carbohydrate component of oxidized (A) and reduced (B) 30 kD protein;

FIGURE 5 is a photographic reproduction of an autoradiogram of an SDS polyacrylamide gel of  $^{125}\text{I}$ -labelled glycosylated (A) and deglycosylated (B) osteogenic protein under non-reducing (1) and reducing (2) conditions;

FIGURE 6 is a photographic reproduction of an autoradiogram of an SDS polyacrylamide gel of peptides produced upon the digestion of the 30 kD osteogenic protein with V-8 protease (B), Endo Lys C protease (C), pepsin (D), and trypsin (E). (A) is control;

FIGURE 7 is a collection of HPLC chromatograms of tryptic peptide digestions of 30 kD BOP (A), the 16 kD subunit (B), and the 18 kD subunit (C);

FIGURE 8 is an HPLC chromatogram of an elution profile on reverse phase C-18 HPLC of the samples recovered from the second heparin-Sepharose chromatography step (see FIGURE 2D). Superimposed is the percent bone formation in each fraction;

FIGURE 9 is a gel permeation chromatogram of an elution profile on TSK 3000/2000 gel of the C-18 purified osteogenic peak fraction. Superimposed is the percent bone formation in each fraction;

FIGURE 10 is a collection of graphs of protein concentration (as indicated by optical absorption) vs. elution volume illustrating the results of human protein fractionation on

heparin-Sepharose I (A), HAP-Ultragel (B), TSK 3000/2000 (C), and heparin-Sepharose II (D). Arrows indicate buffer changes;

FIGURE 11 is a graph showing representative dose response curves for bone-inducing activity in samples from various purification steps including reverse phase HPLC on C-18 (A), Heparin-Sepharose II (B), TSK 3000 (C), HAP-ultragel (D), and Heparin-Sepharose I (E);

FIGURE 12 is a bar graph of radiomorphometric analyses of feline bone defect repair after treatment with an osteogenic device (A), carrier control (B), and demineralized bone (C);

FIGURE 13 is a schematic representation of the DNA sequence and corresponding amino acid sequence of a consensus gene/probe for osteogenic protein (COPO);

FIGURE 14 is a graph of osteogenic activity vs. increasing molecular weight showing peak bone forming activity in the 30 kD region of an SDS polyacrylamide gel;

FIGURE 15 is a photographic representation of a Coomassie blue stained SDS gel showing gel purified subunits of the 30 kD protein;

FIGURE 16 is a pair of HPLC chromatograms of Endo Asp N proteinase digests of the 18 kD subunit (A) and the 16 kD subunit (B);

FIGURE 17 is a photographic representation of the histological examination of bone implants in the rat model: carrier alone (A); carrier and glycosylated osteogenic protein (B); and carrier and deglycosylated osteogenic protein (C). Arrows indicate osteoblasts;

FIGURE 18 is a graph illustrating the activity of xenogenic matrix (deglycolylated bovine matrix); and

FIGURES 19A and 19B are bar graphs showing the specific activity of naturally sourced OP before and after gel elution as measured by calcium content vs. increasing concentrations of proteins (dose curve, in ng).

Description

Purification protocols have been developed which enable isolation of the osteogenic protein present in crude protein extracts from mammalian bone. While each of the separation steps constitute a known separation technique, it has been discovered that the combination of a sequence of separations exploiting the protein's affinity for heparin and for hydroxyapatite (HAP) in the presence of a denaturant such as urea is key to isolating the pure protein from the crude extract. These critical separation steps are combined with separations on hydrophobic media, gel exclusion chromatography, and elution from SDS PAGE.

The isolation procedure enables the production of significant quantities of substantially pure osteogenic protein from any mammalian species, provided sufficient amounts of fresh bone from the species is available. The empirical development of the procedure, coupled with the availability of fresh calf bone, has enabled isolation of substantially pure bovine osteogenic protein (BOP). BOP has been characterized significantly as set forth below; its ability to induce cartilage and ultimately endochondral bone growth in cat, rabbit, and rat have been studied; it has been shown to be able to induce the full developmental cascade of bone formation previously ascribed to unknown protein or proteins in heterogeneous bone extracts; and it may be used to induce formation of endochondral bone in orthopedic defects including non-union fractures. In its native form it is a glycosylated, dimeric protein. However,

it is active in deglycosylated form. It has been partially sequenced. Its primary structure includes the amino acid sequences set forth herein.

Elucidation of the amino acid sequence of BOP enables the construction of pools of nucleic acid probes encoding peptide fragments. Also, a consensus nucleic acid sequence designed as disclosed herein based on the amino acid sequence data, inferred codons for the sequences, and observation of partial homology with known genes, also has been used as a probe. The probes may be used to isolate naturally occurring cDNAs which encode active mammalian osteogenic proteins (OP) as described below using standard hybridization methodology. The mRNAs are present in the cytoplasm of cells of various species which are known to synthesize osteogenic proteins. Useful cells harboring the mRNAs include, for example, osteoblasts from bone or osteosarcoma, hypertrophic chondrocytes, and stem cells. The mRNAs can be used to produce cDNA libraries. Alternatively, relevant DNAs encoding osteogenic protein may be retrieved from cloned genomic DNA libraries from various mammalian species.

These discoveries enable the construction of DNAs encoding totally novel, non-native protein constructs which individually, and combined are capable of producing true endochondral bone. They also permit expression of the natural material, truncated forms, muteins, analogs, fusion proteins,



and various other variants and constructs, from cDNAs retrieved from natural sources or synthesized using the techniques disclosed herein using automated, commercially available equipment. The DNAs may be expressed using well established recombinant DNA technologies in procaryotic or eucaryotic host cells, and may be oxidized and refolded in vitro if necessary for biological activity.

The isolation procedure for obtaining the protein from bone, the retrieval of an osteogenic protein gene, the design and production of recombinant protein, the nature of the matrix, and other material aspects concerning the nature, utility, how to make, and how to use the subject matter claimed herein will be further understood from the following, which constitutes the best method currently known for practicing the various aspects of the invention.

## A - PURIFICATION OF BOP

A1. Preparation of Demineralized Bone

Demineralized bovine bone matrix is prepared by previously published procedures (Sampath and Reddi (1983) Proc. Natl. Acad. Sci. USA 80:6591-6595). Bovine diaphyseal bones (age 1-10 days) are obtained from a local slaughterhouse and used fresh. The bones are stripped of muscle and fat, cleaned of periosteum, demarrowed by pressure with cold water, dipped in cold absolute ethanol, and stored at -20°C. They are then dried and fragmented by crushing and pulverized in a large mill. Care is taken to prevent heating by using liquid nitrogen. The pulverized bone is milled to a particle size between 70-420 µm and is defatted by two washes of approximately two hours duration with three volumes of chloroform and methanol (3:1). The particulate bone is then washed with one volume of absolute ethanol and dried over one volume of anhydrous ether. The defatted bone powder (the alternative method is to obtain Bovine Cortical Bone Powder (75-425 µm) from American Biomaterials) is then demineralized with 10 volumes of 0.5 N HCl at 4°C for 40 min., four times. Finally, neutralizing washes are done on the demineralized bone powder with a large volume of water.

## A2. Dissociative Extraction and Ethanol Precipitation

Demineralized bone matrix thus prepared is dissociatively extracted with 5 volumes of 4 M guanidine-HCl (Gu-HCl), 50mM Tris-HCl, pH 7.0, containing protease inhibitors (5 mM benzamidine, 44 mM 6-aminohexanoic acid, 4.3 mM N-ethylmaleimide, 0.44 mM phenylmethanesulfonyl fluoride) for 16 hr. at 4°C. The suspension is filtered. The supernatant is collected and concentrated to one volume using an ultrafiltration hollow fiber membrane (Amicon, YM-10). The concentrate is centrifuged (8,000 x g for 10 min. at 4°C), and the supernatant is then subjected to ethanol precipitation. To one volume of concentrate is added five volumes of cold (-70°C) absolute ethanol (100%), which is then kept at -70°C for 16 hrs. The precipitate is obtained upon centrifugation at 10,000 x g for 10 min. at 4°C. The resulting pellet is resuspended in 4 l of 85% cold ethanol incubated for 60 min. at -70°C and recentrifuged. The precipitate is again resuspended in 85% cold ethanol (2 l), incubated at -70°C for 60 min. and centrifuged. The precipitate is then lyophilized.

## A3. Heparin-Sepharose Chromatography I

The ethanol precipitated, lyophilized, extracted crude protein is dissolved in 25 volumes of 6 M urea, 50 mM Tris-HCl, pH 7.0 (Buffer A) containing 0.15 M NaCl, and clarified by centrifugation at 8,000 x g for 10 min. The

heparin-Sepharose is column-equilibrated with Buffer A. The protein is loaded onto the column and after washing with three column volume of initial buffer (Buffer A containing 0.15 M NaCl), protein is eluted with Buffer A containing 0.5 M NaCl. The absorption of the eluate is monitored continuously at 280 nm. The pool of protein eluted by 0.5 M NaCl (approximately 1 column volumes) is collected and stored at 4°C.

As shown in FIGURE 2A, most of the protein (about 95%) remains unbound. Approximately 5% of the protein is bound to the column. The unbound fraction has no bone inductive activity when bioassayed as a whole or after a partial purification through Sepharose CL-6B.

#### A4. Hydroxyapaptite-Ultrogel Chromatography

The volume of protein eluted by Buffer A containing 0.5 M NaCl from the heparin-Sepharose is applied directly to a column of hydroxyapaptite-ultrogel (HAP-ultrogel) (LKB Instruments), equilibrated with Buffer A containing 0.5 M NaCl. The HAP-ultrogel is treated with Buffer A containing 500 mM Na phosphate prior to equilibration. The unadsorbed protein is collected as an unbound fraction, and the column is washed with three column volumes of Buffer A containing 0.5 M NaCl. The column is subsequently eluted with Buffer A containing 100 mM Na Phosphate (FIGURE 2B).

The eluted component can induce endochondral bone as measured by alkaline phosphatase activity and histology. As the biologically active protein is bound to HAP in the presence of 6 M urea and 0.5 M NaCl, it is likely that the protein has an affinity for bone mineral and may be displaced only by phosphate ions.

#### A5. Sephacryl S-300 Gel Exclusion Chromatography

Sephacryl S-300 HR (High Resolution, 5 cm x 100 cm column) is obtained from Pharmacia and equilibrated with 4 M guanidine-HCl, 50 mM Tris-HCl, pH 7.0. The bound protein fraction from HA-ultragel is concentrated and exchanged from urea to 4 M guanidine-HCl, 50 mM Tris-HCl, pH 7.0 via an Amicon ultrafiltration YM-10 membrane. The solution is then filtered with Schleicher and Schuell CENTREX disposable microfilters. A sample aliquot of approximately 15 ml containing approximately 400 mg of protein is loaded onto the column and then eluted with 4 M guanidine-HCl, 50 mM Tris-HCl, pH 7.0, with a flow rate of 3 ml/min; 12 ml fractions are collected over 8 hours and the concentration of protein is measured at A<sub>280nm</sub> (FIGURE 2C). An aliquot of the individual fractions is bioassayed for bone formation. Those fractions which have shown bone formation and migrate with an apparent molecular weight of less than 35 kD are pooled and concentrated via an Amicon ultrafiltration system with YM-10 membrane.

#### A6. Heparin-Sepharose Chromatography-II

The pooled osteo-inductive fractions obtained from gel exclusion chromatography are dialysed extensively against distilled water (dH<sub>2</sub>O) and then against 6 M urea, 50 mM Tris-HCl, pH 7.0 (Buffer A) containing 0.1 M NaCl. The dialysate is then cleared through centrifugation. The sample is applied to the heparin-sepharose column (equilibrated with the same buffer). After washing with three column volumes of initial buffer, the column is developed sequentially with Buffer B containing 0.15 M NaCl, and 0.5 M NaCl (FIGURE 2D). The protein eluted by 0.5 M NaCl is collected and dialyzed extensively against distilled water. It is then dialyzed against 30% acetonitrile, 0.1% TFA at 4°C.

#### A7. Reverse Phase HPLC

The protein is further purified by C-18 Vydac silica-based HPLC column chromatography (particle size 5 µm; pore size 300 Å). The osteoinductive fraction obtained from heparin-sepharose-II chromatograph is loaded onto the column, and washed in 0.1% TFA, 10% acetonitrile for five min. As shown in FIGURE 8, the bound proteins are eluted with a linear gradient of 10-30% acetonitrile over 15 min., 30-50% acetonitrile over 60 min, and 50-70% acetonitrile over 10 min at 22°C with a flow rate of 1.5 ml/min and 1.4 ml samples are collected in polycarbonate tubes. Protein is

- 25 -

monitored by absorbance at A<sub>214</sub> nm. Column fractions are tested for the presence of osteoinductive activity, and concanavalin A-blottable proteins. These fractions are then pooled, and characterized biochemically for the presence of 30 kD protein by autoradiography, concanavalin A blotting, and Coomassie blue dye staining. They are then assayed for in vivo osteogenic activity. Biological activity is not found in the absence of 30 kD protein.

#### A8. Gel Elution

The glycosylated or deglycosylated protein is eluted from SDS gels (0.5 mm thickness) for further characterization. <sup>125</sup>I-labelled 30 kD protein is routinely added to each preparation to monitor yields. TABLE 1 shows the various elution buffers that have been tested and the yields of <sup>125</sup>I-labelled protein.

TABLE 1  
Elution of 30 kD Protein from SDS Gel

| <u>Buffer</u>   | <u>% Eluted</u> |
|---|-----------------|
| (1) dH <sub>2</sub> O   | 22              |
| (2) 4 M Guanidine-HCl, Tris-HCl, pH 7.0                       | 2               |
| (3) 4 M Guanidine-HCl, Tris-HCl, pH 7.0,<br>0.5% Triton x 100 | 93              |
| (4) 0.1% SDS, Tris-HCl, pH 7.0                                | 98              |

---

TABLE 2 lists the steps used to isolate the 30 kD or deglycosylated 27 kD gel-bound protein. The standard protocol uses diffusion elution using 4M guanidine-HCl containing 0.5% Triton x 100 in Tris-HCl buffer or in Tris-HCl buffer containing 0.1% SDS to achieve greater than 95% elution of the protein from the 27 or 30 kD region of the gel for demonstration of osteogenic activity in vivo as described in later section.

TABLE 2

Preparation of Gel Eluted Protein

(C-18 Pool or deglycosylated protein plus <sup>125</sup>I-labelled 30 kD protein)

1. Dry using vacuum centrifugation;
  2. Wash pellet with H<sub>2</sub>O;
  3. Dissolve pellet in gel sample buffer (no reducing agent);
  4. Electrophorese on pre-electrophoresed 0.5 mm mini gel;
  5. Cut out 27 or 30 kD protein;
  6. Elute from gel with 0.1% SDS, 50mM Tris-HCl, pH 7.0;
  7. Filter through Centrex membrane;
  8. Concentrate and wash with water in Centricon tube (10 kD membrane).
-



The overall yield of labelled 30 kD protein from the gel elution protocol is 50 - 60% of the loaded sample. Most of the loss occurs in the electrophoresis step, due to protein aggregation and/or smearing.

The yield is 0.5 to 1.0 µg substantially pure osteogenic protein per kg of bone.

A9. Isolation of the 16 kD and 18 kD Species

TABLE 3 summarizes the procedures involved in the preparation of the subunits. Approximately 10 µg of gel eluted 30 kD protein (FIGURE 3) is carboxymethylated and electrophoresed on an SDS-gel. The sample contains  $^{125}\text{I}$ -label to trace yields and to use as an indicator for slicing the 16 kD and 18 kD regions from the gel. FIGURE 15 shows a Coomassie blue stained gel of gel-purified 16 kD and 18 kD proteins.

TABLE 3Isolation of the Subunits of the 30 kD protein

(C-18 pool plus  $^{125}\text{I}$ -labeled 30 kD protein)

1. Electrophoresis on SDS gel.
  2. Cut out 30 kD protein.
  3. Elute with 0.1% SDS, 50 mM Tris-HCl, pH 7.0.
  4. Concentrate and wash with  $\text{H}_2\text{O}$  in Centricon tube (10 kD membranes).
  5. Electrophoresis reduced sample on SDS gel.
  6. Cut out the 16 kD and 18 kD subunits.
  7. Elute with 0.1% SDS, 50 mM Tris-HCl, pH 7.0.
  8. Concentrate and wash with  $\text{H}_2\text{O}$  in Centricon tubes.
  9. Reduce and carboxymethylate in 1% SDS, 0.4 M Tris-HCl, pH 8.5.
  10. Concentrate and wash with  $\text{H}_2\text{O}$  in Centricon tube.
- 

B. Biological Characterization of BOP

B1. Gel Slicing:

Gel slicing experiments confirm that the isolated 30 kD protein is the protein responsible for osteogenic activity.

Gels from the last step of the purification are sliced. Protein in each fraction is extracted in 15 mM Tris-HCl, pH 7.0 containing 0.1% SDS or in buffer containing 4 M guanidine-HCl, 0.5% non-ionic detergent (Triton x 100), 50 mM Tris-HCl. The extracted proteins are desalted, concentrated, and assayed for endochondral bone formation activity. The results are set forth in FIGURE 14. From this figure it is clear that the majority of osteogenic activity is due to protein at 30 kD region of the gel. Activity in higher molecular weight regions is apparently due to protein aggregation. These protein aggregates, when reduced, yields the 16 kD and 18 kD species discussed above.

#### B2. Con A-Sepharose Chromatography:

A sample containing the 30 kD protein is solubilized using 0.1% SDS, 50 mM Tris-HCl, and is applied to a column of concanavalin A (Con A)-Sepharose equilibrated with the same buffer. The bound material is eluted in SDS Tris-HCl buffer containing 0.5 M alpha-methyl mannoside. After reverse phase chromatography of both the bound and unbound fractions, Con A-bound materials, when implanted, result in extensive bone formation. Further characterization of the bound materials show a Con A-blottable 30 kD protein. Accordingly, the 30 kD glycosylated protein is responsible for the bone forming activity.

### B3. Gel Permeation Chromatography:

TSK-3000/2000 gel permeation chromatography in guanidine-HCl alternately is used to achieve separation of the high specific activity fraction obtained from C-18 chromatography (FIGURE 9). The results demonstrate that the peak of bone inducing activity elutes in fractions containing substantially pure 30 kD protein by Coomassie blue staining. When this fraction is iodinated and subjected to autoradiography, a strong band at 30 kD accounts for 90% of the iodinated proteins. The fraction induces bone formation in vivo at a dose of 50 to 100 ng per implant.

### B4. Structural Requirements for Biological Activity

#### B4-1 Activity after Digestion

Although the role of 30 kD osteogenic protein is clearly established for bone induction, through analysis of proteolytic cleavage products we have begun to search for a minimum structure that is necessary for activity in vivo. The results of cleavage experiments demonstrate that pepsin treatment fails to destroy bone inducing capacity, whereas trypsin or CNBr completely abolishes the activity.

- 31 -

An experiment is performed to isolate and identify pepsin digested product responsible for biological activity. The sample used for pepsin digestion was 20% - 30% pure. The buffer used is 0.1% TFA in water. The enzyme to substrate ratio is 1:10. A control sample is made without enzyme. The digestion mixture is incubated at room temperature for 16 hr. The digested product is then separated in 4 M guanidine-HCl using gel permeation chromatography, and the fractions are prepared for in vivo assay. The results demonstrate that active fractions from gel permeation chromatography of the pepsin digest correspond to peptides having an apparent molecular weight range of 8 kD - 10 kD.

#### B4-2 Unglycosylated Protein is Active

In order to understand the importance of the carbohydrates moiety with respect to osteogenic activity, the 30 kD protein has been chemically deglycosylated using HF (see below). After analyzing an aliquot of the reaction product by Con A blot to confirm the absence of carbohydrate, the material is assayed for its activity in vivo. The bioassay is positive (i.e., the deglycosylated protein produces a bone formation response as determined by histological examination shown in FIGURE 17C), demonstrating that exposure to HF did not destroy the biological function of the protein, and thus that the OP does not require carbohydrate for biological activity. In addition, the specific activity of the deglycosylated protein is approximately the same as that of the native glycosylated protein.

#### B5. Specific Activity of BOP

Experiments were performed 1) to determine the half maximal bone-inducing activity based on calcium content of the implant; 2) to estimate proteins at nanogram levels using a gel scanning method; and 3) to establish dose for half maximal bone inducing activity for gel eluted 30 kD BOP. The results demonstrate that gel eluted substantially pure 30 kD osteogenic protein induces bone at less than 5 ng per implant and exhibits half maximal bone differentiation activity at 20 ng per implant (approx. 25 mg). The purification data suggest that osteogenic protein has been purified from bovine bone to 367,307 fold after the final gel elution step with a specific activity of 47,750 bone forming units per mg of protein.

#### B5(a) Half Maximal Bone Differentiation Activity

The bone inducing activity is determined biochemically by the specific activity of alkaline phosphatase and calcium content of the day 12 implant. An increase in the specific activity of alkaline phosphatase indicates the onset of bone formation. Calcium content, on the other hand, is proportional to the amount of bone formed in the implant. The bone formation is therefore calculated by determining calcium content of the implant on day 12 in rats and expressed as bone forming units, which represent the amount that exhibits half maximal bone inducing activity compared to rat demineralized bone matrix. Bone induction

exhibited by intact demineralized rat bone matrix is considered to be the maximal bone-differentiation activity for comparison.

#### B5(b) Protein Estimation Using Gel Scanning Techniques

A standard curve is developed employing known amounts of a standard protein, bovine serum albumin. The protein at varying concentration (50-300 ng) is loaded on a 15% SDS gel, electrophoresed, stained in comassie and destained. The gel is scanned at predetermined settings using a gel scanner at 580 nm. The area covered by the protein band is calculated and a standard curve against concentrations of protein is constructed. A sample with an unknown protein concentration is electrophoresed with BSA as a standard. The lane containing the unknown sample is scanned, and the concentration of protein is determined from the area under the curve.

#### B5(c) Gel Elution and Specific Activity

An aliquot of C-18 highly purified active fraction is subjected to SDS gel and sliced according to molecular weights described in FIGURE 14. Proteins are eluted from the slices in 4 M guanidine-HCl containing 0.5% Triton X-100, desalted, concentrated and assayed for endochondral bone forming activity as determined by calcium content. The C-18 highly active fractions and gel eluted

substantially pure 30 kD osteogenic protein are implanted in varying concentrations in order to determine the half maximal bone inducing activity.

FIGURE 14 shows that the bone inducing activity is due to proteins eluted in the 28-34 kD region. The recovery of activity after the gel elution step is determined by calcium content. FIGURES 19A and 19B represent the bone inducing activity for the various concentrations of 30 kD protein before and after gel elution as estimated by calcium content. The data suggest that the half maximal activity for 30 kD protein before gel elution is 69 ng per 25 mg implant and is 21 ng per 25 mg implant after elution. TABLE 4 describes the yield, total specific activity, and fold purification of osteogenic protein at each step during purification. Approximately 500 ug of heparin sepharose I fraction, 130-150 ug of the HA ultrogel fraction, 10-12 ug of the gel filtration fraction, 4-5 ug of the heparin sepharose II fraction, 0.4-0.5 ug of the C-18 highly purified fraction, and 20-25 ng of the gel eluted, substantially purified fraction is needed per 25 mg of implant for unequivocal bone formation for half maximal activity. Thus, 0.8-1.0 ng purified osteogenic protein per mg. of implant is required to exhibit half maximal bone differentiation activity in vivo.



TABLE 4  
PURIFICATION OF BOP

| Purification Steps    | Protein (mg.) | Biological Activity Units* | Specific Activity Units/mg. | Purification Fold |
|-----------------------|---------------|----------------------------|-----------------------------|-------------------|
| Ethanol Precipitate** | 30,000#       | 4,000                      | 0.13                        | 1                 |
| Heparin Sepharose I   | 1,200#        | 2,400                      | 2.00                        | 15                |
| HA-Ultrogel           | 300#          | 2,307                      | 7.69                        | 59                |
| Gel filtration        | 20#           | 1,600                      | 80.00                       | 615               |
| Heparin Sepharose II  | 5#            | 1,000                      | 200.00                      | 1,538             |
| C-18 HPLC             | 0.070@        | 150                        | 2,043.00                    | 15,715            |
| Gel elution           | 0.004@        | 191                        | 47,750.00                   | 367,307           |

---

Values are calculated from 4 kg of bovine bone matrix (800 g of demineralized matrix).

\* One unit of bone forming activity is defined as the amount that exhibits half maximal bone differentiation activity compared to rat demineralized bone matrix, as determined by calcium content of the implant on day 12 in rats.

# Proteins were measured by absorbance at 280 nm.

@ Proteins were measured by gel scanning method compared to known standard protein, bovine serum albumin.

\*\* Ethanol-precipitated guanidine extract of bovine bone is a weak inducer of bone in rats, possibly due to endogenous inhibitors. This precipitate is subjected to gel filtration and proteins less than 50 kD were separated and used for bioassay.

## C. CHEMICAL CHARACTERIZATION OF BOP

### C1. Molecular Weight and Structure

Electrophoresis of the proteins after the final purification step on non-reducing SDS polyacrylamide gels reveals a diffuse band at about 30 kD as detected by both Coomassie blue staining (FIGURE 3A) and autoradiography.

In order to extend the analysis of BOP, the protein was examined under reducing conditions. FIGURE 3B shows an SDS gel of BOP in the presence of dithiothreitol. Upon reduction, 30 kD BOP yields two species which are stained with Coomassie blue dye: a 16 kD species and an 18 kD species. Reduction causes loss of biological activity. The two reduced BOP species have been analyzed to determine if they are structurally related. Comparison of the amino acid composition and peptide mapping of the two species (as disclosed below) shows little differences, indicating that the native protein may comprise two chains having significant homology.

### C2. Presence of Carbohydrate

The 30 kD protein has been tested for the presence of carbohydrate by Con A blotting after SDS-PAGE and transfer to nitrocellulose paper. The results demonstrate that the 30 kD protein has a high affinity for Con A, indicating that the protein is glycosylated (FIGURE 4A). In addition, the Con A

blots provide evidence for a substructure in the 30 kD region of the gel, suggesting heterogeneity due to varying degrees of glycosylation. After reduction (FIGURE 4B), Con A blots show evidence for two major components at 16 kD and 18 kD. In addition, it has been demonstrated that no glycosylated material remains at the 30 kD region after reduction.

In order to confirm the presence of carbohydrate and to estimate the amount of carbohydrate attached, the 30 kD protein is treated with N-glycanase, a deglycosylating enzyme with a broad specificity. Samples of the  $^{125}\text{I}$ -labelled 30 kD protein are incubated with the enzyme in the presence of SDS for 24 hours at 37°C. As observed by SDS-PAGE, the treated samples appear as a prominent species at about 27 kD (FIGURE 5A). Upon reduction, the 27 kD species is reduced to species having a molecular weight of about 14 kD - 16 kD (FIGURE 5B).

To ensure complete deglycosylation of the 30KD protein, chemical cleavage of the carbohydrate moieties using hydrogen fluoride (HF) is performed. Active osteogenic protein fractions pooled from the C-18 chromatography step are dried in vacuo over  $\text{P}_{205}$  in a polypropylene tube, and 50  $\mu\text{l}$  freshly distilled anhydrous HF at -70°C is added. After capping the tube tightly, the mixture is kept at 0°C in an ice-bath with occasional agitation for 1 hr. The HF is then evaporated using a continuous stream of dry nitrogen gas. The tube is removed from the ice bath and the residue dried in vacuo over  $\text{P}_{205}$  and KOH pellets.

Following drying, the samples are dissolved in 100  $\mu$ l of 50% acetonitrile/0.1% TFA and aliquoted for SDS gel analysis, Con A binding, and biological assay. Aliquots are dried and dissolved in either SDS gel sample buffer in preparation for SDS gel analysis and Con A blotting or 4 M guanidine-HCl, 50 mM Tris-HCl, pH 7.0 for biological assay.

The results show that samples are completely deglycosylated by the HF treatment: Con A blots after SDS gel electrophoreses and transfer to Immobilon membrane showed no binding of Con A to the treated samples, while untreated controls were strongly positive at 30 kD. Coomassie gels of treated samples showed the presense of a 27 kD band instead of the 30 kD band present in the untreated controls.

### C3. Chemical and Enzymatic Cleavage

Cleavage reactions with CNBr are analyzed using Con A binding for detection of fragments associated with carbohydrate. Cleavage reactions are conducted using trifluoroacetic acid (TFA) in the presence and absence of CNBr. Reactions are conducted at 37°C for 18 hours, and the samples are vacuum dried. The samples are washed with water, dissolved in SDS gel sample buffer with reducing agent, boiled and applied to an SDS gel. After electrophoresis, the protein is transferred to Immobilon membrane and visualized by Con A binding. In low concentrations of acid (1%), CNBr cleaves the

majority of 16 kD and 18 kD species to one product, a species about 14 kD. In reactions using 10% TFA, a 14 kD species is observed both with and without CNBr.

Four proteolytic enzymes are used in these experiments to examine the digestion products of the 30 kD protein: 1) V-8 protease; 2) Endo Lys C protease; 3) pepsin; and 4) trypsin. Except for pepsin, the digestion buffer for the enzymes is 0.1 M ammonium bicarbonate, pH 8.3. The pepsin reactions are done in 0.1% TFA. The digestion volume is 100  $\mu$ l and the ratio of enzyme to substrate is 1:10.  $^{125}$ I-labelled 30 kD osteogenic protein is added for detection. After incubation at 37°C for 16 hr., digestion mixtures are dried down and taken up in gel sample buffer containing dithiothreitol for SDS-PAGE. FIGURE 6 shows an autoradiograph of an SDS gel of the digestion products. The results show that under these conditions, only trypsin digests the reduced 16 kD/18 kD species completely and yields a major species at around 12 kD. Pepsin digestion yields better defined, lower molecular weight species. However, the 16 kD/18 kD fragments were not digested completely. The V-8 digest shows limited digestion with one dominant species at 16 kD.

#### C4. Protein Sequencing

To obtain amino acid sequence data, the protein is cleaved with trypsin or Endoproteinase Asp-N (EndoAsp-N). The tryptic digest of reduced and carboxymethylated 30 kD protein (approximately 10  $\mu$ g)

is fractionated by reverse-phase HPLC using a C-8 narrowbore column (13 cm x 2.1 mm ID) with a TFA/acetonitrile gradient and a flow rate of 150  $\mu$ l/min. The gradient employs (A) 0.06% TFA in water and (B) 0.04% TFA in water and acetonitrile (1:4; v:v). The procedure was 10% B for five min., followed by a linear gradient for 70 min. to 80% B, followed by a linear gradient for 10 min. to 100% B. Fractions containing fragments as determined from the peaks in the HPLC profile (FIGURE 7A) are rechromatographed at least once under the same conditions in order to isolate single components satisfactory for sequence analysis.

The HPLC profiles of the similarly digested 16 kD and 18 kD subunits are shown in FIGURES 7B and 7C, respectively. These peptide maps are similar suggesting that the subunits are identical or are closely related.

The 16 kD and 18 kD subunits are digested with EndoAsp-N proteinase. The protein is treated with 0.5  $\mu$ g EndoAsp-N in 50 mM sodium phosphate buffer, pH 7.8 at 36°C for 20 hr. The conditions for fractionation are the same as those described previously for the 30 kD, 16 kD, and 18 kD digests. The profiles obtained are shown in FIGURES 16A and 16B.

Various peptide fragments produced using the foregoing procedures have been analyzed in an automated amino acid sequencer (Applied Biosystems 470A with 120A on-line PTH analysis). The following sequence data has been obtained:

- (1) S-F-D-A-Y-Y-C-S-G-A-C-Q-F-P-M-P-K;
- (2) S-L-K-P-S-N-Y-A-T-I-Q-S-I-V;
- (3) A-C-C-V-P-T-E-L-S-A-I-S-M-L-Y-L-D-E-N-E-K;
- (4) M-S-S-L-S-I-L-F-F-D-E-N-K;
- (5) S-Q-E-L-Y-V-D-F-Q-R;
- (6) F-L-H-C-Q-F-S-E-R-N-S;
- (7) T-V-G-Q-L-N-E-Q-S-S-E-P-N-I-Y;
- (8) L-Y-D-P-M-V-V;
- (9) V-G-V-V-P-G-I-P-E-P-C-C-V-P-E;
- (10) V-D-F-A-D-I-G;
- (11) V-P-K-P-C-C-A-P-T;
- (12) I-N-I-A-N-Y-L;
- (13) D-N-H-V-L-T-M-F-P-I-A-I-N;
- (14) D-E-Q-T-L-K-K-A-R-R-K-Q-W-I-?-P;
- (15) D-I-G-?-S-E-W-I-I-?-P;
- (16) S-I-V-R-A-V-G-V-P-G-I-P-E-P-?-?-V;
- (17) D-?-I-V-A-P-P-Q-Y-H-A-F-Y;
- (18) D-E-N-K-N-V-V-L-K-V-Y-P-N-M-T-V-E;
- (19) S-Q-T-L-Q-F-D-E-Q-T-L-K-?-A-R-?-K-Q;
- (20) D-E-Q-T-L-K-K-A-R-R-K-Q-W-I-E-P-R-N-?-A-R-R-Y-L;
- (21) A-R-R-K-Q-W-I-E-P-R-N-?-A-?-R-Y-?-?-V-D; and
- (22) R-?-Q-W-I-E-P-?-N-?-A-?-?-Y-L-K-V-D-?-A-?-?-G



#### C5. Amino Acid Analysis

Samples of oxidized (30 kD) and reduced (16 kD and 18 kD) BOP are electrophoresed on a gel and transferred to Immobilon for hydrolysis and amino acid analysis using conventional, commercially available reagents to derivatize samples and HPLC using the PicO Tag (Millipore) system. The composition data generated by amino acid analyses of 30 kD BOP is reproducible, with some variation in the number of residues for a few amino acids, especially cysteine and isoleucine.

Composition data obtained are shown in TABLE

5.

TABLE 5  
BOP Amino Acid Analyses

| <u>Amino Acid</u>            | <u>30 kD</u> | <u>16 kD</u> | <u>18 kD</u> |
|------------------------------|--------------|--------------|--------------|
| Aspartic Acid/<br>Asparagine | 22           | 14           | 15           |
| Glutamic Acid/<br>Glutamine  | 24           | 14           | 16           |
| Serine                       | 24           | 16           | 23           |
| Glycine                      | 29           | 18           | 26           |
| Histidine                    | 5            | *            | 4            |
| Arginine                     | 13           | 6            | 6            |
| Threonine                    | 11           | 6            | 7            |
| Alanine                      | 18           | 11           | 12           |
| Proline                      | 14           | 6            | 6            |
| Tyrosine                     | 11           | 3            | 3            |
| Valine                       | 14           | 8            | 7            |
| Methionine                   | 3            | 0            | 2            |
| Cysteine**                   | 16           | 14           | 12           |
| Isoleucine                   | 15           | 14           | 10           |
| Leucine                      | 15           | 8            | 9            |
| Phenylalanine                | 7            | 4            | 4            |
| Tryptophan                   | ND           | ND           | ND           |
| Lysine                       | 12           | 6            | 6            |

\*This result is not integrated because histidine is present in low quantities.

\*\*Cysteine is corrected by percent normally recovered from performic acid hydrolysis of the standard protein.

The results obtained from the 16 kD and 18 kD subunits, when combined, closely resemble the numbers obtained from the native 30 kD protein. The high figures obtained for glycine and serine are most likely the result of gel elution.

#### D. PURIFICATION OF HUMAN OSTEOGENIC PROTEIN

Human bone is obtained from the Bone Bank, (Massachusetts General Hospital, Boston, MA), and is milled, defatted, demarrowed and demineralized by the procedure disclosed above. 320 g of mineralized bone matrix yields 70 - 80 g of demineralized bone matrix. Dissociative extraction and ethanol precipitation of the matrix gives 12.5 g of guanidine-HCl extract.

One third of the ethanol precipitate (0.5 g) is used for gel filtration through 4 M guanidine-HCl (FIGURE 10A). Approximately 70-80 g of ethanol precipitate per run is used. In vivo bone inducing activity is localized in the fractions containing proteins in the 30 kD range. They are pooled and equilibrated in 6 M urea, 0.5 M NaCl buffer, and applied directly onto a HAP column; the bound protein

is eluted stepwise by using the same buffer containing 100 mM and 500 mM phosphate (FIGURE 10B). Bioassay of HAP bound and unbound fractions demonstrates that only the fraction eluted by 100 mM phosphate has bone inducing activity in vivo. The biologically active fraction obtained from HAP chromatography is subjected to heparin-Sepharose affinity chromatography in buffer containing low salt; the bound proteins are eluted by 0.5 M NaCl (FIGURE 10C). Assaying the heparin-Sepharose fractions shows that the bound fraction eluted by 0.5 M NaCl have bone-inducing activity. The active fraction is then subjected to C-18 reverse phase chromatography. (FIGURE 10D).

The active fraction can then be subjected to SDS-PAGE as noted above to yield a band at about 30 kD comprising substantially pure human osteogenic protein.

#### E. BIOSYNTHETIC PROBES FOR ISOLATION OF GENES ENCODING NATIVE OSTEOGENIC PROTEIN

##### E-1 PROBE DESIGN

A synthetic consensus gene shown in FIGURE 13 was designed as a hybridization probe based on amino acid predictions from homology with the TGF-beta gene family and using human codon bias as found in human TGF-beta. The designed consensus sequence was then constructed using known techniques involving assembly of oligonucleotides manufactured in a DNA synthesizer.

Tryptic peptides derived from BOP and sequenced by Edman degradation provided amino acid sequences that showed strong homology with the Drosophila DPP protein sequence (as inferred from the gene), the Xenopus Vg1 protein, and somewhat less homology to inhibin and TGF-beta, as demonstrated below in TABLE 6.

TABLE 6

| <u>protein</u>      | <u>amino acid sequence</u> | <u>homology</u> |
|---------------------|----------------------------|-----------------|
| ( <u>BOP</u> )      | SFDAYYCSGACQFPS            | (9/15 matches)  |
|                     | ***** * * *                |                 |
| ( <u>DPP</u> )      | GYDAYYCHGKCPFFL            |                 |
| <hr/>               |                            |                 |
| ( <u>BOP</u> )      | SFDAYYCSGACQFPS            | (6/15 matches)  |
|                     | * * * * *                  |                 |
| ( <u>Vg1</u> )      | GYMANCYGECPYPL             |                 |
| <hr/>               |                            |                 |
| ( <u>BOP</u> )      | SFDAYYCSGACQFPS            | (5/15 matches)  |
|                     | * * * * *                  |                 |
| ( <u>inhibin</u> )  | GYHANYCEGECPSHI            |                 |
| <hr/>               |                            |                 |
| ( <u>BOP</u> )      | SFDAYYCSGACQFPS            | (4/15 matches)  |
|                     | * * * * *                  |                 |
| ( <u>TGF-beta</u> ) | GYHANFCLGPCPYIW            |                 |
| <hr/>               |                            |                 |
| ( <u>BOP</u> )      | K/RACCVPTELSAISMLYLDEN     | (12/20 matches) |
|                     | ***** * * * *              |                 |
| ( <u>Vg1</u> )      | LPCCVPTKMSPISMLFYDNN       |                 |
| <hr/>               |                            |                 |

- 48 -

(BOP) K/RACCVPTELSAISMLYLDEN  
\* \* \* \* \* (12/20 matches)  
(inhibin) KSCCVPTKLRPMSMLYYDDG

---

(BOP) K/RACCVPTELSAISMLYLDE  
\* \* \* \* \* (6/19 matches)  
(TGF-beta) APCCVPQALEPLPIVYYVG

---

(BOP) K/RACCVPTELSAISMLYLDEN  
\* \* \* \* \* (12/20 matches)  
(DPP) KACCVPTQLDSVAMLYLNDQ

---

(BOP) LYVDF  
\* \* \* \* \* (5/5 matches)  
(DPP) LYVDF

---

(BOP) LYVDF  
\* \* \* \* (4/5 matches)  
(Vgl) LYVEF

---

(BOP) LYVDF  
\* \* \* \* (4/5 matches)  
(TGF-beta) LYIDF

---

(BOP) LYVDF  
\* \* (2/5 matches)  
(inhibin) FFVSF

---

\*-match

In determining the amino acid sequence of an osteogenic protein (from which the nucleic acid sequence can be determined), the following points were considered: (1) the amino acid sequence determined by Edman degradation of osteogenic protein tryptic fragments is ranked highest as long as it has a strong signal and shows homology or conservative changes when aligned with the other members of the gene family; (2) where the sequence matches for all four proteins, it is used in the synthetic gene sequence; (3) matching amino acids in DPP and Vgl are used; (4) If Vgl or DPP diverged but either one were matched by inhibin or by TGF-beta, this matched amino acid is chosen; (5) where all sequences diverged, the DPP sequence is initially chosen, with a later plan of creating the Vgl sequence by mutagenesis kept as a possibility. In addition, the consensus sequence is designed to preserve the disulfide crosslinking and the apparent structural homology.

One purpose of the originally designed synthetic consensus gene sequence, designated COP0, (see FIGURE 13), was to serve as a probe to isolate natural genes. For this reason the DNA was designed using human codon bias. Alternatively, probes may be constructed using conventional techniques comprising a group of sequences of nucleotides which encode any portion of the amino acid sequence of the osteogenic protein produced in accordance with the foregoing isolation procedure. Use of such pools of probes also will enable isolation of a DNA encoding the intact protein.

E-2      Retrieval of Genes Encoding Osteogenic  
Protein from Genomic Library

A human genomic library (Maniatis-library) carried in lambda phage (Charon 4A) was screened using the COP0 consensus gene as probe. The initial screening was of 500,000 plaques (10 plates of 50,000 each). Areas giving hybridization signal were punched out from the plates, phage particles were eluted and plated again at a density of 2000-3000 plaques per plate. A second hybridization yielded plaques which were plated once more, this time at a density of ca 100 plaques per plate allowing isolation of pure clones. The probe (COP0) is a 300 base pair BamHI-PstI fragment restricted from an amplification plasmid which was labeled using alpha 32 dCTP according to the random priming method of Feinberg and Vogelstein (1984) Anal. Biochem. 137: 266-267. Prehybridization was done for 1 hr in 5x SSPE, 10x Denhardt's mix, 0.5% SDS at 50°C. Hybridization was overnight in the same solution as above plus probe. The washing of nitrocellulose membranes was done, once cold for 5 min. in 1x SSPE with 0.1% SDS and twice at 50°C for 2 x 30 min. in the same solution. Using this procedure, twenty-four positive clones were found. Two contained a gene never before reported designated OP1, osteogenic protein-1 described below. Two others yielded the genes corresponding to BMP-2b, one yielded BMP-3 (see PCT US 87/01537).



Southern blot analysis of lambda #13 DNA showed that an approximately 3kb BamHI fragment hybridized to the probe. (See FIGURE 1B). This fragment was isolated and subcloned into a bluescript vector (at the BamHI site). The clone was further analyzed by Southern blotting and hybridization to the COP0 probe. This showed that a 1 kb (approx.) EcoRI fragment strongly hybridized to the probe. This fragment was subcloned into the EcoRI site of a bluescript vector, and sequenced. Analysis of this sequence showed that the fragment encoded the carboxy terminus of a protein, named osteogenic protein-1 (OP1). The protein was identified by amino acid homology with the TGF-beta family. For this comparison cysteine patterns were used and then the adjacent amino acids were compared. Consensus splice signals were found where amino acid homologies ended, designating exon intron boundaries. Three exons were combined to obtain a functional TGF-beta-like domain containing seven cysteines. Two introns were deleted by looping out via primers bridging the exons using the single stranded mutagenesis method of Kunkel. Also, upstream of the first cysteine, an EcoRI site and an asp-pro junction for acid cleavage were introduced, and at the 3' end a PstI site was added by the same technique. Further sequence information (penultimate exon) was obtained by sequencing the entire insert. The sequencing was done by generating a set of unidirectionally deleted clones (Ozkaynak, E., and Putney, S. (1987) *Biotechniques*, 5:770-773). The obtained sequence covers about 80% of the TGF-beta-like region of OP1 and is set forth in FIGURE

1A. The complete sequence of the TGF-beta like region was obtained by first subcloning all EcoRI generated fragments of lambda clone #13 DNA and sequencing a 4 kb fragment that includes the first portion of the TGF-beta like region (third exon counting from end) as well as sequences characterized earlier. The gene on an EcoRI to PstI fragment was inserted into an E. coli expression vector controlled by the trp promoter-operator to produce a modified trp LE fusion protein with an acid cleavage site. The OP1 gene encodes amino acids corresponding substantially to a peptide found in sequences of naturally sourced material. The amino acid sequence of what is believed to be its active region is set forth below:

```

      1      10      20      30      40
OP1      LYVSFR-DLGWQDWIIAPEGYAAYYCEGECAFLNS
              50      60      70
      YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
              80      90     100
      ISVLYFDDSSNVILKKYRNMVVRACGCH

```

A longer active sequence is:

```

                                     -5
                                     HQRQA
      1      10      20      30      40
OP1      CKKHELYVSFR-DLGWQDWIIAPEGYAAYYCEGECAFLNS
              50      60      70
      YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
              80      90     100
      ISVLYFDDSSNVILKKYRNMVVRACGCH

```

The amino acid sequence of what is believed to be the active regions encoded by the other three native genes retrieved using the consensus probe are:

|         |   |    |     |    |    |
|---------|---|----|-----|----|----|
| CBMP-2a | 1   | 10 | 20  | 30 | 40 |
|         | CKRHPLYVDFS-DVGWNDWIVAPPGYHAFYCHGECPFPLAD |    |     |    |    |
|         | 50  | 60 | 70  |    |    |
|         | HLNSTN--H-AIVQTLVNSVNS-K-IPKACCVPTLSA     |    |     |    |    |
|         | 80  | 90 | 100 |    |    |
|         | ISMLYLDENEKVVLKNYQDMVVEGCGCR              |    |     |    |    |
|         |   |    |     |    |    |
| CBMP-2b | 1   | 10 | 20  | 30 | 40 |
|         | CRRHSLYVDFS-DVGWNDWIVAPPGYQAFYCHGDCPFPLAD |    |     |    |    |
|         | 50  | 60 | 70  |    |    |
|         | HLNSTN--H-AIVQTLVNSVNS-S-IPKACCVPTLSA     |    |     |    |    |
|         | 80  | 90 | 100 |    |    |
|         | ISMLYLDEYDKVVLKNYQEMVVEGCGCR              |    |     |    |    |
|         |   |    |     |    |    |
| CBMP-3  | 1   | 10 | 20  | 30 | 40 |
|         | CARRYLKVDFA-DIGWSEWIISPKSFDAYYCSGACQFMPK  |    |     |    |    |
|         | 50  | 60 | 70  |    |    |
|         | SLKPSN--H-ATIQSIVRAVGVPGIPEPCCVPEKMSS     |    |     |    |    |
|         | 80  | 90 | 100 |    |    |
|         | LSILFFDENKNVVLKVYPNMTVESACR               |    |     |    |    |

### E-3 Probing cDNA Library

Another example of the use of pools of probes to enable isolation of a DNA encoding the

intact protein is shown by the following. Cells known to express the protein (e.g., osteoblasts or osteosarcoma) are extracted to isolate total cytoplasmic RNA. An oligo-dT column can be used to isolate mRNA. This mRNA can be size fractionated by, for example, gel electrophoresis. The fraction which includes the mRNA of interest may be determined by inducing transient expression in a suitable host cell and testing for the presence of osteogenic protein using, for example, antibody raised against peptides derived from the tryptic fragments of osteogenic protein in an immunoassay. The mRNA fraction is then reverse transcribed to single stranded cDNA using reverse transcriptase; a second complementary DNA strand can then be synthesized using the cDNA as a template. The double-standard DNA is then ligated into vectors which are used to transfect bacteria to produce a cDNA library.

The radiolabelled consensus sequence, portions thereof, and/or synthetic deoxy oligonucleotides complementary to codons for the known amino acid sequences in the osteogenic protein may be used to identify which of the DNAs in the cDNA library encode the full length osteogenic protein by standard DNA-DNA hybridization techniques.

The cDNA may then be integrated in an expression vector and transfected into an appropriate host cell for protein expression. The host may be a prokaryotic or eucaryotic cell since the former's inability to glycosylate osteogenic protein will not effect the protein's enzymatic activity. Useful host cells include Saccharomyces, E. coli, and various mammalian cell cultures. The vector may additionally encode various signal sequences for protein secretion and/or may encode osteogenic protein as a fusion protein. After being translated, protein may be purified from the cells or recovered from the culture medium.

#### E4. Gene Preparation

Natural gene sequences and cDNAs retrieved as described above may be used for expression. The genes above may also be produced by assembly of chemically synthesized oligonucleotides. 15-100mer oligonucleotides may be synthesized on a Biosearch DNA Model 8600 Synthesizer, and purified by polyacrylamide gel electrophoresis (PAGE) in Tris-Borate-EDTA buffer (TBE). The DNA is then electroeluted from the gel. Overlapping oligomers may be phosphorylated by T4 polynucleotide kinase and ligated into larger blocks which may also be purified by PAGE.

#### E5. Expression

The genes can be expressed in appropriate prokaryotic hosts such as various strains of E. coli, and also in bacillus, yeasts, and various animal cells such as CHO, myeloma, etc. Generally, expression may be achieved using many cell types and expression systems well known to those skilled in the art. For example, if the gene is to be expressed in E. coli, an expression vector based on pBR322 and containing a synthetic trp promoter operator and the modified trp LE leader may be used. The vector can be opened at the EcoRI and PSTI restriction sites, and, for example, an OP gene fragment can be inserted between these two sites. The OP protein is joined to the leader protein via a hinge region having the sequence Asp-Pro. This hinge permits chemical cleavage of the fusion protein with dilute acid at the Asp-Pro site.

#### E6. Production of Active Proteins

The following procedure may be followed for production of active recombinant proteins. E. coli cells containing the fusion proteins are lysed. The fusion proteins are purified by differential solubilization. Cleavage is conducted with dilute acid, and the resulting cleavage products are passed through a Sephacryl-200HR or SP Trisacryl column to separate the cleaved proteins. The reduced OP fractions are then subjected to HPLC on a semi-prep C-18 column.

- 57 -

Conditions for refolding of OP were at pH 8.0 using 50 mM Tris-HCl and 6M Gu-HCl. Samples were refolded for 18 hours at 4°C.

These procedures have been used to express in E. coli on the active protein designated OP1 having the amino acid sequence set forth above (longer species).

Refolding may not be required if the proteins are expressed in animal cells.

#### MATRIX PREPARATION

##### A. General Consideration of Matrix Properties

The carrier described in the bioassay section, *infra*, may be replaced by either a biodegradable-synthetic or synthetic-inorganic matrix (e.g., HAP, collagen, tricalcium phosphate, or polylactic acid, polyglycolic acid and various copolymers thereof). Also xenogeneic bone may be used if pretreated as described below.

Studies have shown that surface charge, particle size, the presence of mineral, and the methodology for combining matrix and osteogenic protein all play a role in achieving successful bone induction. Perturbation of the charge by chemical

modification abolishes the inductive response. Particle size influences the quantitative response of new bone; particles between 75 and 420  $\mu\text{m}$  elicit the maximum response. Contamination of the matrix with bone mineral will inhibit bone formation. Most importantly, the procedures used to formulate osteogenic protein onto the matrix are extremely sensitive to the physical and chemical state of both the osteogenic protein and the matrix.

The sequential cellular reactions at the interface of the bone matrix/OP implants are complex. The multistep cascade includes: binding of fibrin and fibronectin to implanted matrix, chemotaxis of cells, proliferation of fibroblasts, differentiation into chondroblasts, cartilage formation, vascular invasion, bone formation, remodeling, and bone marrow differentiation.

A successful carrier for osteogenic protein must perform several important functions. It must bind osteogenic protein and act as a slow release delivery system, accommodate each step of the cellular response during bone development, and protect the osteogenic protein from nonspecific proteolysis. In addition, selected materials must be biocompatible in vivo and biodegradable; the carrier must act as a temporary scaffold until replaced completely by new bone. Biocompatibility requires that the matrix not induce significant inflammation when implanted and not be rejected by the host



animal. Biodegradability requires that the matrix be slowly absorbed by the body of the host during development of new bone or cartilage. Polylactic acid (PLA), polyglycolic acid (PGA), and various combinations have different dissolution rates in vivo. In bones, the dissolution rates can vary according to whether the implant is placed in cortical or trabecular bone.

Matrix geometry, particle size, the presence of surface charge, and porosity or the presence of interstices among the particles of a size sufficient to permit cell infiltration, are all important to successful matrix performance. It is preferred to shape the matrix to the desired form of the new bone and to have dimensions which span non-union defects. Rat studies show that the new bone is formed essentially having the dimensions of the device implanted.

The matrix may comprise a shape-retaining solid made of loosely adhered particulate material, e.g., with collagen. It may also comprise a molded, porous solid, or simply an aggregation of close-packed particles held in place by surrounding tissue. Masticated muscle or other tissue may also be used. Large allogeneic bone implants can act as a carrier for the matrix if their marrow cavities are cleaned and packed with particles and the dispersed osteogenic protein.

B. Preparation of Biologically Active Allogenic Matrix

Demineralized bone matrix is prepared from the dehydrated diaphyseal shafts of rat femur and tibia as described herein to produce a bone particle size which pass through a 420  $\mu$  sieve. The bone particles are subjected to dissociative extraction with 4 M guanidine-HCl. Such treatment results in a complete loss of the inherent ability of the bone matrix to induce endochondral bone differentiation. The remaining insoluble material is used to fabricate the matrix. The material is mostly collagenous in nature, and upon implantation, does not induce cartilage and bone. All new preparations are tested for mineral content and false positives before use. The total loss of biological activity of bone matrix is restored when an active osteoinductive protein fraction or a pure protein is reconstituted with the biologically inactive insoluble collagenous matrix. The osteoinductive protein can be obtained from any vertebrate, e.g., bovine, porcine, monkey, or human, or produced using recombinant DNA techniques.

C. Preparation of Deglycosylated Bone Matrix for Use in Xenogenic Implant

When osteogenic protein is reconstituted with collagenous bone matrix from other species and implanted in rat, no bone is formed. This suggests that while the osteogenic protein is xenogenic (not

- 61 -

species specific), the matrix is species specific and cannot be implanted cross species perhaps due to intrinsic immunogenic or inhibitory components. Thus, heretofore, for bone-based matrices, in order for the osteogenic protein to exhibit its full bone inducing activity, a species specific collagenous bone matrix was required.

The major component of all bone matrices is Type I collagen. In addition to collagen, extracted bone includes non-collagenous proteins which may account for 5% of its mass. Many non-collagenous components of bone matrix are glycoproteins. Although the biological significance of the glycoproteins in bone formation is not known, they may present themselves as potent antigens by virtue of their carbohydrate content and may constitute immunogenic and/or inhibitory components that are present in xenogenic matrix.

It has now been discovered that a collagenous bone matrix may be used as a carrier to effect bone inducing activity in xenogenic implants, if one first removes the immunogenic and inhibitory components from the matrix. The matrix is deglycosylated chemically using, for example, hydrogen fluoride to achieve this purpose.

- 62 -

Bovine bone residue prepared as described above is sieved, and particles of the 74-420  $\mu$ M are collected. The sample is dried in vacuo over P<sub>2</sub>O<sub>5</sub>, transferred to the reaction vessel and anhydrous hydrogen fluoride (HF) (10-20 ml/g of matrix) is then distilled onto the sample at -70°C. The vessel is allowed to warm to 0°C and the reaction mixture is stirred at this temperature for 120 min. After evaporation of the HF in vacuo, the residue is dried thoroughly in vacuo over KOH pellets to remove any remaining traces of acid.

Extent of deglycosylation can be determined from carbohydrate analysis of matrix samples taken before and after treatment with HF, after washing the samples appropriately to remove non-covalently bound carbohydrates.

The deglycosylated bone matrix is next treated as set forth below:

- 1) suspend in TBS (Tris-buffered Saline) 1g/200 ml and stir at 4°C for 2 hrs or in 6 M urea, 50 mM Tris-HCl, 500 mM NaCl, pH 7.0 (UTBS), and stir at RT for 30 min.;
- 2) centrifuge and wash with TBS or UTBS as in step 1); and
- 3) centrifuge; discard supernatant; water wash residue; and then lyophilize.

## FABRICATION OF OSTEOGENIC DEVICE

Fabrication of osteogenic devices using any of the matrices set forth above with any of the osteogenic proteins described above may be performed as follows.

A. Ethanol precipitation

In this procedure, matrix was added to osteogenic protein in guanidine-HCl. Samples were vortexed and incubated at a low temperature. Samples were then further vortexed. Cold absolute ethanol was added to the mixture which was then stirred and incubated. After centrifugation (microfuge high speed) the supernatant was discarded. The reconstituted matrix was washed with cold concentrated ethanol in water and then lyophilized.

B. Acetonitrile Trifluoroacetic Acid  
Lyophilization

In this procedure, osteogenic protein in an acetonitrile trifluoroacetic acid (ACN/TFA) solution was added to the carrier. Samples were vigorously vortexed many times and then lyophilized.

- 64 -

C. Urea Lyophilization

For those proteins that are prepared in urea buffer, the protein is mixed with the matrix, vortexed many times, and then lyophilized. The lyophilized material may be used "as is" for implants.

IN VIVO RAT BIOASSAY

Substantially pure BOP, BOP-rich extracts comprising protein having the properties set forth above, and several of the recombinant proteins have been incorporated in matrices to produce osteogenic devices, and assayed in rat for endochondral bone. Studies in rats show the osteogenic effect to be dependent on the dose of osteogenic protein dispersed in the osteogenic device. No activity is observed if the matrix is implanted alone. The following sets forth guidelines for how the osteogenic devices disclosed herein might be assayed for determining active fractions of osteogenic protein when employing the isolation procedure of the invention, and evaluating protein constructs and matrices for biological activity.

A. Subcutaneous Implantation

The bioassay for bone induction as described by Sampath and Reddi (Proc. Natl. Acad. Sci. USA (1983) 80: 6591-6595), herein incorporated by

- 65 -

reference, is used to monitor the purification protocols for endochondral bone differentiation activity. This assay consists of implanting the test samples in subcutaneous sites in allogeneic recipient rats under ether anesthesia. Male Long-Evans rats, aged 28-32 days, were used. A vertical incision (1 cm) is made under sterile conditions in the skin over the thoracic region, and a pocket is prepared by blunt dissection. Approximately 25 mg of the test sample is implanted deep into the pocket and the incision is closed with a metallic skin clip. The day of implantation is designated as day of the experiment. Implants were removed on day 12. The heterotopic site allows for the study of bone induction without the possible ambiguities resulting from the use of orthotopic sites.

B. Cellular Events

The implant model in rats exhibits a controlled progression through the stages of matrix induced endochondral bone development including: (1) transient infiltration by polymorphonuclear leukocytes on day one; (2) mesenchymal cell migration and proliferation on days two and three; (3) chondrocyte appearance on days five and six; (4) cartilage matrix formation on day seven; (5) cartilage calcification on day eight; (6) vascular invasion, appearance of osteoblasts, and formation of new bone on days nine and ten; (7) appearance of osteoblastic and bone remodeling and dissolution of

- 66 -

the implanted matrix on days twelve to eighteen; and (8) hematopoietic bone marrow differentiation in the ossicle on day twenty-one. The results show that the shape of the new bone conforms to the shape of the implanted matrix.

C. Histological Evaluation

Histological sectioning and staining is preferred to determine the extent of osteogenesis in the implants. Implants are fixed in Bouins Solution, embedded in parafilm, cut into 6-8 mm sections. Staining with toluidine blue or hemotoxylin/eosin demonstrates clearly the ultimate development of endochondrial bone. Twelve day implants are usually sufficient to determine whether the implants show bone inducing activity.

D. Biological Markers

Alkaline phosphatase activity may be used as a marker for osteogenesis. The enzyme activity may be determined spectrophotometrically after homogenization of the implant. The activity peaks at 9-10 days in vivo and thereafter slowly declines. Implants showing no bone development by histology should have little or no alkaline phosphatase activity under these assay conditions. The assay is useful for quantitation and obtaining an estimate of bone formation very quickly after the implants are removed from the rat. Alternatively the amount of bone formation can be determined by measuring the calcium content of the implant.



- 67 -

Implants containing osteogenic protein at several levels of purity have been tested to determine the most effective dose/purity level, in order to seek a formulation which could be produced on a commercial scale. The results are measured by specific activity of alkaline phosphatase, calcium content, and histological examination. As noted previously, the specific activity of alkaline phosphatase is elevated during onset of bone formation and then declines. On the other hand, calcium content is directly proportional to the total amount of bone that is formed. The osteogenic activity due to osteogenic protein is represented by "bone forming units". For example, one bone forming unit represents the amount of protein that is needed for half maximal bone forming activity as compared to rat demineralized bone matrix as control and determined by calcium content of the implant on day 12.

E.        Results

Dose curves are constructed for bone inducing activity in vivo at each step of the purification scheme by assaying various concentrations of protein. FIGURE 11 shows representative dose curves in rats as determined by alkaline phosphatase. Similar results are obtained when represented as bone forming units. Approximately 10-12 µg of the TSK-fraction, 3-4

- 68 -

µg of heparin-Sepharose-II fraction, 0.4-0.5 µg of the C-18 column purified fraction, and 20-25 ng of gel eluted highly purified 30 kD protein is needed for unequivocal bone formation (half maximum activity). 20-25 ng of the substantially pure protein per 25 mg of implant is normally sufficient to produce endochondral bone. Thus, 1-2 ng osteogenic protein per mg of implant is a reasonable dosage, although higher dosages may be used. (See section IB5 on specific activity of osteogenic protein.)

OPl expressed as set forth above (longer version), when assayed for activity histologically, induced cartilage and bone formation as evidenced by the presence of numerous chondrocytes in many areas of the implant and by the presence of osteoblasts surrounding vascular endothelium forming new matrix.

Deglycosylated xenogenic collagenous bone matrix (example: bovine) has been used instead of allogenic collagenous matrix to prepare osteogenic devices (see previous section) and bioassayed in rat for bone inducing activity in vivo. The results demonstrate that xenogenic collagenous bone matrix after chemical deglycosylation induces successful endochondral bone formation (FIGURE 19). As shown by specific activity of alkaline phosphatase, it is evident that the deglycosylated xenogenic matrix induced bone whereas untreated bovine matrix did not.

- 69 -

Histological evaluation of implants suggests that the deglycosylated bovine matrix not only has induced bone in a way comparable to the rat residue matrix but also has advanced the developmental stages that are involved in endochondral bone differentiation. Compared to rat residue as control, the HF treated bovine matrix contains extensively remodeled bone. Ossicles are formed that are already filled with bone marrow elements by 12 days. This profound action as elicited by deglycosylated bovine matrix in supporting bone induction is reproducible and is dose dependent with varying concentration of osteogenic protein.

#### ANIMAL EFFICACY STUDIES

Substantially pure osteogenic protein from bovine bone (BOP), BOP-rich osteogenic fractions having the properties set forth above, and several recombinant proteins have been incorporated in matrices to produce osteogenic devices. The efficacy of bone-inducing potential of these devices was tested in cat and rabbit models, and found to be potent inducers of osteogenesis, ultimately resulting in formation of mineralized bone. The following sets forth guidelines as to how the osteogenic devices disclosed herein might be used in a clinical setting.

##### A. Feline Model

The purpose of this study is to establish a large animal efficacy model for the testing of the

- 70 -

osteogenic devices of the invention, and to characterize repair of massive bone defects and simulated fracture non-union encountered frequently in the practice of orthopedic surgery. The study is designed to evaluate whether implants of osteogenic protein with a carrier can enhance the regeneration of bone following injury and major reconstructive surgery by use of this large mammal model. The first step in this study design consists of the surgical preparation of a femoral osteotomy defect which, without further intervention, would consistently progress to non-union of the simulated fracture defect. The effects of implants of osteogenic devices into the created bone defects were evaluated by the following study protocol.

#### A-1. Procedure

Sixteen adult cats weighing less than 10 lbs. undergo unilateral preparation of a 1 cm bone defect in the right femur through a lateral surgical approach. In other experiments, a 2 cm bone defect was created. The femur is immediately internally fixed by lateral placement of an 8-hole plate to preserve the exact dimensions of the defect. There are three different types of materials implanted in the surgically created feline femoral defects: group I (n = 3) is a control group which undergo the same plate fixation with implants of 4 M guanidine-HCl-treated (inactivated) feline demineralized bone matrix powder (Gu-HCl-DBM) (360 mg); group II (n = 3) is a positive control group

- 71 -

implanted with biologically active feline demineralized bone matrix powder (DBM) (360 mg); and group III (n = 10) undergo a procedure identical to groups I-II, with the addition of osteogenic protein onto each of the Gu-HCl-DBM carrier samples. To summarize, the group III osteogenic protein-treated animals are implanted with exactly the same material as the group I animals, but with the singular addition of osteogenic protein.

All animals are allowed to ambulate ad libitum within their cages post-operatively. All cats are injected with tetracycline (25 mg/kg SQ each week for four weeks) for bone labelling. All but four group III animals are sacrificed four months after femoral osteotomy.

#### A-2. Radiomorphometrics

In vivo radiomorphometric studies are carried out immediately post-op at 4, 8, 12 and 16 weeks by taking a standardized x-ray of the lightly anesthetized animal positioned in a cushioned x-ray jig designed to consistently produce a true antero-posterior view of the femur and the osteotomy site. All x-rays are taken in exactly the same fashion and in exactly the same position on each animal. Bone repair is calculated as a function of mineralization by means of random point analysis. A final specimen radiographic study of the excised bone is taken in two planes after sacrifice. X-ray

results are shown in FIGURE 12, and displaced as percent of bone defect repair. To summarize, at 16 weeks, 60% of the group III femurs are united with average 86% bone defect regeneration. By contrast, the group I Gu-HCl-DMB negative-control implants exhibit no bone growth at four weeks, less than 10% at eight and 12 weeks, and 16% ( $\pm 10\%$ ) at 16 weeks with one of the five exhibiting a small amount of bridging bone. The group II DMB positive-control implants exhibited 18% ( $\pm 3\%$ ) repair at four weeks, 35% at eight weeks, 50% ( $\pm 10\%$ ) at twelve weeks and 70% ( $\pm 12\%$ ) by 16 weeks, a statistical difference of  $p < 0.01$  compared to osteogenic protein at every month. One of the three (33%) is united at 16 weeks.

### A-3. Biomechanics

Excised test and normal femurs are immediately studied by bone densitometry, wrapped in two layers of saline-soaked towels, placed in two sealed plastic bags, and stored at  $-20^{\circ}\text{C}$  until further study. Bone repair strength, load to failure, and work to failure are tested by loading to failure on a specially designed steel 4-point bending jig attached to an Instron testing machine to quantitate bone strength, stiffness, energy absorbed and deformation to failure. The study of test femurs and normal femurs yield the bone strength (load) in pounds and work to failure in joules. Normal femurs exhibit a strength of 96 ( $\pm 12$ ) pounds. osteogenic protein-implanted femurs exhibited 35 ( $\pm 4$ ) pounds, but when corrected for surface area at the site of

- 73 -

fracture (due to the "hourglass" shape of the bone defect repair) this correlated closely with normal bone strength. Only one demineralized bone specimen was available for testing with a strength of 25 pounds, but, again, the strength correlated closely with normal bone when corrected for fracture surface area.

#### A-4. Histomorphometry/Histology

Following biomechanical testing the bones are immediately sliced into two longitudinal sections at the defect site, weighed, and the volume measured. One-half is fixed for standard calcified bone histomorphometrics with fluorescent stain incorporation evaluation, and one-half is fixed for decalcified hemotoxylin/eosin stain histology preparation.

#### A-5. Biochemistry

Selected specimens from the bone repair site (n=6) are homogenized in cold 0.15 M NaCl, 3 mM NaHCO<sub>3</sub>, pH 9.0 by a Spex freezer mill. The alkaline phosphatase activity of the supernatant and total calcium content of the acid soluble fraction of sediment are then determined.

#### A-6. Histopathology

The final autopsy reports reveal no unusual or pathologic findings noted at necropsy of any of the animals studied. Portion of all major organs are

- 74 -

preserved for further study. A histopathological evaluation is performed on samples of the following organs: heart, lung, liver, both kidneys, spleen, both adrenals, lymph nodes, left and right quadriceps muscles at mid-femur (adjacent to defect site in experimental femur). No unusual or pathological lesions are seen in any of the tissues. Mild lesions seen in the quadriceps muscles are compatible with healing responses to the surgical manipulation at the defect site. Pulmonary edema is attributable to the euthanasia procedure. There is no evidence of any general systemic effects or any effects on the specific organs examined.

#### A-7. Feline Study Summary

The 1 cm and 2 cm femoral defect cat studies demonstrate that devices comprising a matrix containing disposed osteogenic protein can: (1) repair a weight-bearing bone defect in a large animal; (2) consistently induces bone formation shortly following (less than two weeks) implantation; and (3) induce bone by endochondral ossification, with a strength equal to normal bone, on a volume for volume basis. Furthermore, all animals remained healthy during the study and showed no evidence of clinical or histological laboratory reaction to the implanted device. In this bone defect model, there was little or no healing at control bone implant sites. The results provide evidence for the successful use of osteogenic devices to repair large, non-union bone defects.



B. Rabbit Model:

B1. Procedure and Results

The purpose of this study is to establish a model in which there is minimal or no bone growth in the control animals, so that when bone induction is tested, only a strongly inductive substance will yield a positive result. Defects of 1.5 cm are created in the ulnae of rabbits with implantation of osteogenic devices or no implant.

Eight mature (greater than 10 lbs) New Zealand White rabbits with epiphyseal closure documented by X-ray were studied. Of these eight animals (one animal each was sacrificed at one and two weeks), 11 ulnae defects are followed for the full course of the eight week study. In all cases (n = 7) following osteo-periosteal bone resection, the no implant animals establish no radiographic union by eight weeks. All no implant animals develop a thin "shell" of bone growing from surrounding bone present at four weeks and, to a slightly greater degree, by eight weeks. In all cases (n = 4), radiographic union with marked bone induction is established in the osteogenic protein-implanted animals by eight weeks. As opposed to the no implant repairs, this bone repair is in the site of the removed bone.

- 76 -

Radiomorphometric analysis reveal 90% osteogenic protein-implant bone repair and 18% no-implant bone repair at sacrifice at eight weeks. At autopsy, the osteogenic protein bone appears normal, while "no implant" bone sites have only a soft fibrous tissue with no evidence of cartilage or bone repair in the defect site.

#### B-2. Allograft Device

In another experiment, the marrow cavity of the 1.5 cm ulnar defect is packed with activated osteogenic protein rabbit bone powder and the bones are allografted in an intercalary fashion. The two control ulnae are not healed by eight weeks and reveal the classic "ivory" appearance. In distinct contrast, the osteogenic protein-treated implants "disappear" radiographically by four weeks with the start of remineralization by six to eight weeks. These allografts heal at each end with mild proliferative bone formation by eight weeks.

This type of device serves to accelerate allograft repair.

#### B-3. Summary

These studies of 1.5 cm osteo-periosteal defects in the ulnae of mature rabbits show that: (1) it is a suitable model for the study of bone growth; (2) "no implant" or Gu-HCl negative control implants yield a small amount of periosteal-type bone, but not

medullary or cortical bone growth; (3) osteogenic protein-implanted rabbits exhibited proliferative bone growth in a fashion highly different from the control groups; (4) initial studies show that the bones exhibit 50% of normal bone strength (100% of normal correlated vol:vol) at only eight weeks after creation of the surgical defect; and (5) osteogenic protein-allograft studies reveal a marked effect upon both the allograft and bone healing.

The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

What is claimed is:

Claims

1. An osteogenic device for implantation in a mammal, said device comprising:

a biocompatible, in vivo biodegradable matrix defining pores of a dimension sufficient to permit influx, proliferation and differentiation of migratory progenitor cells from the body of said mammal; and

substantially pure osteogenic protein capable of inducing endochondral bone formation in said mammal disposed in said matrix and accessible to said cells.

2. Substantially pure osteogenic protein capable of inducing endochondral bone formation in a mammal when disposed within a matrix implanted in said mammal.

3. The device of claim 1 wherein said matrix comprises close-packed particulate matter having a particle size within the range of 70-420  $\mu\text{m}$ .

4. The device of claim 1 wherein said matrix comprises demineralized, protein-extracted, particulate, allogenic bone.

5. The device of claim 1 wherein said matrix comprises collagen, hydroxyapatite, tricalcium phosphate, polymers comprising lactic acid monomer units, polymers comprising glycolic acid monomer units, demineralized, guanidine-extracted allogenic bone, or a mixture thereof.

6. The device of claim 1 wherein said matrix is shaped to span a non-union fracture in said mammal.

7. The device of claim 1 disposed within the marrow cavity of allogenic bone.

8. The device of claim 1 wherein said matrix comprises demineralized, protein extracted, particulate, deglycosylated xenogenic bone.

9. The device of claim 8 wherein said matrix is treated with a protease.

10. The invention of claim 1 or 2 wherein said osteogenic protein is unglycosylated.

11. The invention of claim 10 wherein said osteogenic protein has an apparent molecular weight of about 27 kD when oxidized as determined by comparison to molecular weight standards in SDS-polyacrylamide gel electrophoresis.

12. The invention of claim 1 or 2 wherein said osteogenic protein is glycosylated.

13. The invention of claim 12 wherein said osteogenic protein has an apparent molecular weight of about 30 kD when oxidized as determined by comparison to molecular weight standards in SDS-polyacrylamide gel electrophoresis.

- 80 -

14. The invention of claim 1 or 2 wherein said osteogenic protein comprises a pair of polypeptide chains.

15. The invention of claim 14 wherein one chain of said pair of polypeptide chains has an apparent molecular weight of about 14 kD and the other has an apparent molecular weight of about 16 kD, both as determined after reduction by comparison to molecular weight standards in SDS-polyacrylamide gel electrophoresis.

16. The invention of claim 14 wherein one chain of said pair of polypeptide chains has an apparent molecular weight of about 16 kD and the other has an apparent molecular weight of about 18 kD, both as determined after reduction by comparison to molecular weight standards in SDS-polyacrylamide gel electrophoresis.

17. The invention of claim 1 or 2 wherein said osteogenic protein has the approximate amino acid composition set forth below:

| <u>Amino acid</u><br><u>residue</u> | <u>Rel. no.</u><br><u>res./molec.</u> | <u>Amino acid</u><br><u>residue</u> | <u>Rel. no.</u><br><u>res./molec.</u> |
|-------------------------------------|---------------------------------------|-------------------------------------|---------------------------------------|
| Aspartic acid/                      | 22                                    | Tyrosine                            | 11                                    |
| Asparagine                          |                                       | Valine                              | 14                                    |
| Glutamic acid/                      | 24                                    | Methionine                          | 3                                     |
| Glutamine                           |                                       | Cysteine                            | 16                                    |
| Serine                              | 24                                    | Isoleucine                          | 15                                    |

|           |    |               |    |
|-----------|----|---------------|----|
| Glycine   | 29 | Leucine       | 15 |
| Histidine | 5  | Proline       | 14 |
| Arginine  | 13 | Phenylalanine | 7  |
| Threonine | 11 | Tryptophan    | ND |
| Alanine   | 18 |               |    |
| Lysine    | 12 |               |    |

18. The invention of claim 1 or 2 wherein said osteogenic protein comprises the amino acid sequence:

VPKPCCAPT.

19. The invention of claim 1 or 2 wherein the half maximum bone inducing activity of said protein is 0.8 to 1.0 ng per mg of said matrix.

20. A method of inducing local cartilage or bone formation in a mammal comprising the step of implanting the device of claim 1 in said mammal at a locus accessible to migratory progenitor cells of said mammal.

21. A method of inducing endochondral bone formation in a mammal comprising the step of implanting the device of claim 1 in said mammal at a locus accessible to migratory progenitor cells of said mammal.

22. A method of inducing endochondral bone formation in a non-union fracture in a mammal comprising the step of implanting in the fracture in said mammal the device of claim 6.

23. The invention of claim 1 or 2 wherein the protein comprises the sequence:

```

      1      10      20      30      40
OP1      LYVSFR-DLGWQDWIIAPEGYAAYYCEGECAPLNS
              50      60      70
      YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
              80      90     100
      ISVLYFDDSSNVILKKYRNMVVRACGCH
  
```

24. The device of claim 1 or 2 wherein the protein comprises the sequence:

```

              -5
              HQRQA
      1      10      20      30      40
OP1      CKKHELYVSFR-DLGWQDWIIAPEGYAAYYCEGECAPLNS
              50      60      70
      YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
              80      90     100
      ISVLYFDDSSNVILKKYRNMVVRACGCH
  
```

25. The device of claim 1 or 2 wherein the protein comprises the sequence:

```

      1      10      20      30      40
CBMP-2a  CKRHPLYVDFS-DVGWNDWIVAPPGYHAFYCHGECPFPLAD
              50      60      70
      HLNSTN--H-AIVQTLVNSVNS-K-IPKACCVPTLSA
              80      90     100
      ISMLYLDENEKVVLKKNYQDMVVEGCGCR
  
```



26. The device of claim 1 or 2 wherein the protein comprises the sequence:

```

      1      10      20      30      40
CBMP-2b  CRRHSLYVDFS-DVGWNDWIVAPPGYQAFYCHGDCPFPLAD
              50      60      70
      HLNSTN--H-AIVQTLVNSVNS-S-IPKACCVPTLSA
              80      90     100
      ISMLYLDEYDKVVLKKNYQEMVVEGCGCR

```

27. The device of claim 1 or 2 wherein the protein comprises the sequence:

```

      1      10      20      30      40
CBMP-3   CARRYLKVDFA-DIGWSEWIISPKSFDAYYCSGACQFPMPK
              50      60      70
      SLKPSN--H-ATIQSIVRAVGVPGIPEPCCVPEKMSS
              80      90     100
      LSILFFDENKNVVLKVYPNMTVESACR

```

28. A DNA sequence encoding an amino acid sequence sufficiently duplicative of that of the sequence encoded by the gene of FIGURE 1A such that said encoded sequence induces bone or cartilage formation when implanted in a mammal in association with a matrix.

29. The DNA of claim 28 encoding the same amino acid sequence as the gene set forth in FIGURE 1A.

30. The DNA sequence of claim 28 encoding:

```
      1      10      20      30      40
OP1      LYVSFR-DLGWQDWIIAPEGYAAYYCEGECAFLNS
              50      60      70
      YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
              80      90     100
      ISVLYFDDSSNVILKKYRNMVVRACGCH
```

31. The DNA sequence of claim 28 encoding:

```
                                -5
                                HQRQA
      1      10      20      30      40
OP1      CKKHELYVSFR-DLGWQDWIIAPEGYAAYYCEGECAFLNS
              50      60      70
      YMNATN--H-AIVQTLVHFINPET-VPKPCCAPTQLNA
              80      90     100
      ISVLYFDDSSNVILKKYRNMVVRACGCH
```

32. A cell line engineered to express the protein of claim 2.

33. The device of claim 1 wherein said matrix comprises demineralized, protein extracted, particulate xenogenic bone treated with HF.

## FIG. 1A-1

|   |     |     |     |     |     |     |
|---|-----|-----|-----|-----|-----|-----|
| 10  | 20  | 30  | 40  | 50  | 60  | 70  |
| GGAGGTATAGGAGCTCTCTTCGATTTTAGCAAAACAGAGTCCGAAGATCTAAGGAGAGAGCTGGGGGTTTGACTCC  |     |     |     |     |     |     |
| SacI BglII  |     |     |     |     |     |     |
| 85  | 95  | 105 | 115 | 125 | 135 | 145 |
| GAGAGCTCGAGCAGTCCCAAGACCTGGTCTTGACTCAGGAGTTAGACTCCACTCAGAGGCTGACTGTCTCCAGG    |     |     |     |     |     |     |
| SacI PflMI  |     |     |     |     |     |     |
| 160   | 170 | 180 | 190 | 200 | 210 | 220 |
| GTCTACACCTCTAAGGGCGACACTGGGCTCAAGCAGACTGCCGTTTCTATATGGGATGAGCCTTCACAGGGCAG    |     |     |     |     |     |     |
| 235   | 245 | 255 | 265 | 275 | 285 | 295 |
| CCAGTTGGGATGGGTTGAGGTTTGGCTGTAGACATCAGAAACCCCAAGTCAAAATGCGCTTCAACCAGTAGAAAATT |     |     |     |     |     |     |
| 310   | 320 | 330 | 340 | 350 | 360 | 370 |
| CACCAGCCCGCAGAGCTAAGGTTGGGTGGACATTAGGGTTGGTGTATCCAGGAGCTCAACAGTGTCTCTGAGCC    |     |     |     |     |     |     |
| SacI  |     |     |     |     |     |     |
| 385   | 395 | 405 | 415 | 425 | 435 | 445 |
| CCAGCTCCTTCTGCCCCACCCACCACATCTTCAGTGTCTCTCTCTCAAGGCCACAGCTGTAGTTGGCCAGGGGG    |     |     |     |     |     |     |
| PvuII BglI  |     |     |     |     |     |     |
| 460   | 470 | 480 | 490 | 500 | 510 | 520 |
| GCTTCATTATTTTGTCTCCTGGGCAGTAGGAGGAAGAGAAATGAATGTCTCTCCATGGGTCTTTCTTAGGAATGT   |     |     |     |     |     |     |
| NcoI  |     |     |     |     |     |     |
| 535   | 545 | 555 | 565 | 575 | 585 | 595 |
| GGGAACTTTTCCAGAAGTCTCTATGTCTTTTAGTTTGTGTTGGGTCACTTGCCCTTCCCTGAACCACTTCCTGAC   |     |     |     |     |     |     |
| 610   | 620 | 630 | 640 | 650 | 660 | 670 |
| TCCTGGACAGGATGTGCACATGATGAGCTTACGCTTTGGGATCTAATAGTGACTTTACAAAGCCTCTTTTGAGAAGG |     |     |     |     |     |     |
| ApaLI EspI  |     |     |     |     |     |     |
| 685   | 695 | 705 | 715 | 725 | 735 | 745 |
| TGACATTGGAACCAAGGCTTGAGCAGACACAAACAAGATTGCAGGGAGGGGCAATTGCAGGTGGAGGAAACGGCAC  |     |     |     |     |     |     |
| BspMI-  |     |     |     |     |     |     |
| 760   | 770 | 780 | 790 | 800 | 810 | 820 |
| ATGCAAGAGCCCTGCGTGGGAGTGAGCTTGGTGTGGTCAATCAGTTGTTCAGAGCACACCCGGGCCCTGTTCAGCA  |     |     |     |     |     |     |
| ApaI EcoO   |     |     |     |     |     |     |

## FIG. 1A-2

835 845 855 865 875 885 895  
 GGCACAGCCTGGGCCCTGCTCTGAGTATGACAGAGAGCCCCCTGGGAAGTTGTAGGTGGAGAAAGACAGGTCAATGA  
 910 920 930 940 950 960 970  
 CTAGGAAAAAGCAATCCCTCTGTGTGGGGTGAAGGAGTTGCAGTGTGTGTGAGAGAGAGACAAGACAGAC  
 985 995 1005 1015 1025 1035 1045  
 AGACAGACACTTCTCAATGTTTACAAGTGCTCAGGCCCTGACCCCGAATGCTTCCAAATTTACGTAGTTCTTGGA  
 EcoO BsmI+ SnaBI  
 1060 1070 1080 1090 1100 1110 1120  
 ACCCCCTGTATCATTTTCACTACTCAAAGAAACCTCGGGAGTGTTTTCTTCTGAAAGTTCATCAGGTTTGTGACTC  
 1135 1145 1155 1165 1175 1185 1195  
 TCTGCTGTCTCATTTCTTCTGTGTGGTGGTGATGGTTGTCTCCAGGCCCTGTCCCGCATCTCTTGTGCCC  
 EcoO  
 1210 1220 1230 1240 1250 1260 1270  
 CTGCAGAGGGATGAGTGTGTGGGCCCTCACGAGTTGAGGTTGTTCATAAGCAGATCTCTTTGAGCAGGGCGCCT  
 PstI EcoO BglII NarI Ps  
 1285 1295 1305 1315 1325 1335 1345  
 GCAGTGGCCTTGTGTGAGGCTGGAGGGGTTTCGATTCCCTTATGGAATCCAGGCAGATGTAGCATTTAAACAACA  
 tI DraI  
 1360 1370 1380 1390 1400 1410 1420  
 CACGTGTATAAAGAAACCAAGTGTCCGCAGAAAGTTCCAGAAAGTATTATGGGATAAGACTACATGAGAGAGGAA  
 1435 1445 1455 1465 1475 1485 1495  
 TGGGGCATTGGCACCTCCCTTAGTAGGGCCTTTGTCTGGGGGTAGAAATGAGTTTAAAGGCAGGTTAGACCCCTCGA  
 EcoO BspMI-  
 1510 1520 1530 1540 1550 1560 1570  
 ACTGGCTTTTGAATCGGGAATTTACCCCCAGCCGTTCTGTGCTTCATTTGCTGTTTCACATCACTGCCCTAAGATG  
 1585 1595 1605 1615 1625 1635 1645  
 GAGGAACCTTTGATGTGTGTGTTTCTTCTCCTCACTGGGCTCTGCTTCTTCACTTCTTCAATGCAGAGAA  
 1660 1670 1680 1690 1700 1710 1720  
 CAGCAGCAGGCCACAGAGCGCCCTTGTAAAGAACGACGAGCTGTATGTACGCTTCCGAGACCTGGGCTGGCAGG  
 StuI BspMI  
 1735 1745 1755 1765 1775 1785 1795  
 TAAGGGGCTGGCTGGTCTGTCTTGGGTGTGGGCCCTCTGGCGTGGCTCCACAGCAGCGGGTGTCTGTGTCTCA  
 ApaI  
 EcoO

3 / 19

1810 1820 1830 1840 1850 1860 1870  
 GTCTTGTCTCTGCTGCTTAAAGACTCCAGTATCAAGTGGCTCGCTAGGGAAGGTAAGTGGCTAAGGA  
 1885 1895 1905 1915 1925 1935 1945  
 TACAGGG.....(APPROX. 1000 BASES).....GGGAGCCAGCATGGGTGATGCCATTATGA  
 1960 1970 1980 1990 2000 2010 2020  
 GTTATTAGCCTCTCTGGCAGGTGGGCAACCGAGGATGGAGGTTTGTTTAAGGTGAACCTGCCAGTGTGTGACCA  
 BglI BspMI-  
 2035 2045 2055 2065 2075 2085 2095  
 CCTAGTGGGTAGAGCTGATGATTGCCTCACACCGGAGCTCCTTCCTGTGCCCGGTTCTGTCCAGAACACACAGC  
 aIII SacI  
 MI  
 2110 2120 2130 2140 2150 2160 2170  
 CATGGATGTCCATTTAGGATCAGCCAAAGCCCGTCTTGTCCTTCATTTTATTTATGTTTATTAGAAATGGG  
 col  
 2185 2195 2205 2215 2225 2235 2245  
 GTCTTGCTGTGTCACCCAGGCTGGGTGTCAGTGTGTGATCATAGCTACCGCAGCTTTGACGCCGTCTTCCCCT  
 TthlIII  
 2260 2270 2280 2290 2300 2310 2320  
 CAGTCTAAGCTTGGACTATAGGCCAAGACTATAGAGTGGTCTCTTCCATTCCTTTGGGACCATGAGAGG  
 HindIII BstXI  
 2335 2345 2355 2365 2375 2385 2395  
 CCACCCATGTTTCCCTGCTGGGCCCTGCTGCTCAGAAAGGCATGGTCTGAGGCTTTCACCTTGGTGTGTGAG  
 ApaI  
 EcoO  
 2410 2420 2430 2440 2450 2460 2470  
 CCTTCGTGGTGGTTTCTTTCAGCATGGGTTGGGATGCTGTGCTCAGGCTTCTGCATGGTTTCCCACACTCTCTT  
 2485 2495 2505 2515 2525 2535 2545  
 CTCCTCCTCAGGACTGGATCATCGCGCCTGAAGGCTACGCGGCTACTACTGTGAGGGGGAGTGTGCCCTTCCCCTC  
 MstII BssHII  
 2560 2570 2580 2590 2600 2610 2620  
 TGAACCTCCTACATGAACGCCCAACCAACCGCCATCGTGCAGACGCTGGTGGGTGTACGCCCATCTTGGGGTGTGG  
 Bs  
 2635 2645 2655 2665 2675 2685 2695  
 TCACCTGGGCGGCAGGCTGGGGGGCCACAGATCCTGCTGCCCTCCAAGCTGGGGCCTGAGTAGATGTACAGCCC  
 tEII BglI EcoO

## FIG. 1A-3

SUBSTITUTE SHEET

**FIG. 1A-4**

2710 2720 2730 2740 2750 2760 2770  
 ATTGCCATGTCATGACTTTTGGGGGCCCTTGGCCGTTAAATAAAATCAAAATTTGTTACTTTTATGACTGGTTT

2785 2795 2805 2815 2825 2835 2845  
 GGTATAAGAGGAGTATAATCTTCGACCCCTGGAGTTCAATTTTCTCTAATTTTAAAGTAACTAAAGTTGT

2860 2870 2880 2890 2900 2910 2920  
 ATGGGCTCCTTTGAGGATGCTTGTAGTATTGTGGTGCTGGTTACGGTGCCTAAGAGCACTGGGCCCTGCTTCA

2935 2945 2955 2965 2975 2985 2995  
 TTTTCCAGTAGAGGAAACAGGTAAACAGATGAGAAATTTTCAGTGAGGGGCACAGTGATCAGAAAGCGGCCAGCAG

3010 3020 3030 3040 3050 3060 3070  
 GATAATGGGATGGAGAGATGAGTGGGGACCCATGGGCCATTTCAAGTTAAATTTTCAGTCGGGTCAACAGGAAGAT

3085 3095 3105 3115 3125 3135 3145  
 TCCATGTGATAATGAGATTAAACGTGCCCCAGTCACGGGCACACTCAGTAGGTGTTATTCTCTGCTCTGCCAACAGCA

3160 3170 3180 3190 3200 3210 3220  
 ACCATAGTTGATAAGAGCTGTTAGGGATTTTGTCTTTTGTAGTAATCCAAGGTTCAAGGACCTTGGTTATGTA

3235 3245 3255 3265 3275 3285 3295  
 GCTCCCTGTCAATGAACATCATCTGAGCCCTTCTCTGCTACTGATCATCCACCCCTGCCCTTGAATGCTTCTAGTGAC

3310 3320 3330 3340 3350 3360 3370  
 AGAGAGCTCACTACCAGGACTACTCCCTCTTTTCATTTAGTAATCTGCCCTCTCTTTCTTCTGTCCCTGTCTGT

3385 3395 3405 3415 3425 3435 3445  
 GTGTTAAGTCTCGAGAAAAATCTCATCTATCCCTTTTCATTTGATTCTGCTCTTTGAGGGCAGGGTTTTTGT

3460 3470 3480 3490 3500 3510 3520  
 CTTTGTGTTGTTTTTAAAGTGTGGTTTTTCCAAAGCCCTTGCTCCCTCTCAATTGAAACTTCAAGCCCTCAT

3535 3545 3555 3565 3575 3585 3595  
 TGGGATTGAAGGTCCTTAGGCTGGAAACAGAGAGTCTCCCAACCTGTTCCCTGGCCTGGATGTGCTGTGCTG

ECOO NcoI  
 BstEII  
 EcoO  
 BsmI+

SacI  
 EcoMstII

**FIG. 1A-5**

3610 3620 3630 3640 3650 3660 3670  
 TGCCAGTATCCCCTGGAAGTGCCAGGCATGTCTCCCGGCTGCCAGGGACACATCTCTATCTCTCTCAACCC  
 3685 3695 3705 3715 3725 3735 3745  
 CTGCTTCATGGCCCATGGAACAGAGAGTGCCATCGCCCTGTGTGCACCTACTTCCATCAGTATTTCCACCAGAGAT  
 BglI NcoI ApaLI BglI  
 3760 3770 3780 3790 3800 3810 3820  
 CTGCAGGATCAAGTGAATTTCTCCAGGGATTGTGAAATGATGCGGATGTGGTCATGTTTAAAGGGGCAACTGT  
 I EcoRI DraI  
 PstI  
 3835 3845 3855 3865 3875 3885 3895  
 CTTCTAGAGAGTCCCTGATGAAATGCTTCCAGAGGAAATGAGCTGATGGCTGGAATTTGCTTTAAATCATTTCAAG  
 XbaI DraI  
 3910 3920 3930 3940 3950 3960 3970  
 GTGGAGCAGGTGGGGAAGGTATGGATGTGTAAGAGTTTGAAATTGTCCATCATATAAATGTGTAAAGCATGCT  
 BspMI- SphI  
 3985 3995 4005 4015 4025 4035 4045  
 GGCCTATGTACAGCAGTCACAGCCTGGAGTGGTAACAGAGTGCCAGTCACCTGATGCTCAAGCCTGGCACCTACAG  
 4060 4070 4080 4090 4100 4110 4120  
 TTGCTGGAAACCCAGAAGTTTCACGTTGAAACAAACAGGACAGTGGAATCTCTGGCCCTGTCTTTGAACACGCTGGC  
 4135 4145 4155 4165 4175 4185 4195  
 AGATCTGCTAACACTGATCTTGGTTGGCTGCCGTCAGCTTAGGTTGAGTGGGGTCTTTCCCTTAGTTTGCTTAGT  
 BglII  
 4210 4220 4230 4240 4250 4260 4270  
 CCCCGCTATTCCCTATTGTCTTTACCTCGGTCTATTTTGGCTTATCAGTGGACCTCAGAGGCACTCATAGGCATTT  
 4285 4295 4305 4315 4325 4335 4345  
 GAGTCTATGTGTCCTGTGCCACATCCTCTGTAAAGGTGCAGAGAAAGTCCATGAGCAAGATGGAGCACTTCTAGTG  
 4360 4370 4380 4390 4400 4410 4420  
 GGTCCAAGTCAGGGACACTATTTCAGCAATCTACAGTGCACAGGGCAGTTTCCCCAACAGAGAATTACCTGGTCTCTG  
 ApaLI  
 4435 4445 4455 4465 4475 4485 4495  
 AATGTCGGATCTGGCCCCCTTCCTTCCCCACTGTATAATGTGAAACCTCTATGCTTTGTTCCCCCTTGCTCTGCAAA  
 4510 4520 4530 4540 4550 4560 4570  
 ACAGGGATAATCCCAGAACTGAGTTGTCCATGTAAAGTGCTTAGAACAGGGAGTGCTTGGCTTGGGGAGTGTCAC  
 Bs

## FIG. 1A-6

4585 4595 4605 4615 4625 4635 4645  
 CTGCAGTCAATTATGCCCAGACAGGATGTTTCTTTATAGAAACGTGGAGGCCAGTTAGAACGACTCACCCT  
 PMI+  
 PstI  
 4660 4670 4680 4690 4700 4710 4720  
 TCTCACCACCTGCCCATGTTTGGTGTGTGTTTCAGGTCCACTTCATCAACCCGGAAACGGTGCCCAAGCCCTGCT  
 PflMI  
 4735 4745 4755 4765 4775 4785 4795  
 GTGCGCCACGCAGCTCAATGCCATCTCCGTCCCTCTACTTCGATGACAGCTCCCAACGTCTCCTGAAGAAATACA  
 4810 4820 4830 4840  
 GAAACATGGTGGTCCGGCCTGTGGCTGCCACTAGCTCCTCCGA



**FIG. 1B**

|  |       |       |     |       |       |       |
|--|-------|-------|-----|-------|-------|-------|
| CONSENSUS PROBE  | 20    | 30    | 40  | 50    | 60    | 70    |
| GATCCTAATGGGCTGTACGTGGACTTCCAGCGCGACGTGGGCTGGGACACTGGATCATCGCCCCCGTCG    |       |       |     |       |       |       |
| **   | **    | **    | **  | **    | **    | **    |
| TTGTAAGAAAGCAGAGCTGTATGTACAGCTTCCGAGACCTGGGCTGGCAGGACTGGATCATCGCGCCTGAAG |       |       |     |       |       |       |
| OP4  | 28    | 38    | 48  | 58    | 68    | 78    |
|  | 88    |       |     |       |       |       |
| ACTTCGACGCCCTACTACTGCTCCGGAGCCTGCCAGTTCCCTCTGCGGATCACTTCAACAGCACCAACCA   | 80    | 90    | 100 | 110   | 120   | 130   |
| **   | **    | ***** | **  | ***** | **    | ***** |
| GCTACGCGCGCTACTACTGTGAGGGGAGTGTGCTTCCCTCTGAACCTCCTACATGAACGCCACCAACCA    | 98    | 108   | 118 | 128   | 138   | 148   |
|  | 158   |       |     |       |       |       |
| CGCGGTGGTGCAGACCCCTGGTGAACAACATGAACCCCGGCAAGTACCCAGCCCTGCTGCGTGCCCAAC    | 150   | 160   | 170 | 180   | 190   | 200   |
| *****  | ***** | ***** | **  | ***** | ***** | ***** |
| CGCCATCGTGCAGACGCTGCTCCACTTCAATCAACCCGGAAACGGTGCCCAAGCCCTGCTGTGCGGCCACG  | 168   | 178   | 188 | 198   | 208   | 218   |
|  | 228   |       |     |       |       |       |
| GAGCTGTCCGCCCATCAGCATGCTGTACCTGGACGAGAAATCCACCCTGGTGTGAAGAACTACCAGGAGA   | 220   | 230   | 240 | 250   | 260   | 270   |
| *****  | ***** | **    | *** | **    | ***   | ***** |
| CAGCTCAATGCCCATCTCCGTCCTCTACTTCGATGACAGCTCCAACGTCTCCTGAAGAAATACAGAAACA   | 238   | 248   | 258 | 268   | 278   | 288   |
|  | 298   |       |     |       |       |       |
| TGACCGTGGTGGGCTGCGGCTGCCGCTAACTGCA                                       | 290   | 300   | 310 |       |       |       |
| **   | **    | ***** | *** | **    |       |       |
| TGGTGGTCCGGGCGCTGTGGCTGCCACTAGCTCCT                                      | 308   | 318   | 328 |       |       |       |




FIG. 2B




FIG. 2D




FIG. 2A




FIG. 2C

FIG. 3A FIG. 3B




FIG. 4A FIG. 4B



FIG. 5A



FIG. 5B



10 / 19

FIG. 6 A FIG. 6 B FIG. 6 C FIG. 6 D FIG. 6 E




FIG. 15



— 18K SUBUNIT  
— 16K SUBUNIT

11 / 19




FIG. 7A




FIG. 7B




FIG. 7C

SUBSTITUTE SHEET

12 / 19




FIG. 8




FIG. 9




FIG. 10

14 / 19




FIG. 11




FIG. 12

SUBSTITUTE SHEET



15 / 19

## FIG. 13

10 20 30 40 50  
GATCCTAATGGGCTGTACGTGGACTTCCAGCGCGACGTGGGCTGGGACGA  
D P N G L Y V D F Q R D V G W D D

60 70 80 90 100  
CTGGATCATCGCCCCCGTCGACTTCGACGCCTACTACTGCTCCGGAGCCT  
W I I A P V D F D A Y Y C S G A

110 120 130 140 150  
GCCAGTTCCTCTGCGGATCACTTCAACAGCACCAACCACGCCGTGGTG  
C Q F P S A D H F N S T N H A V V

160 170 180 190 200  
CAGACCCTGGTGAACAACATGAACCCCGGCAAGGTACCCAAGCCCTGCTG  
Q T L V N N M N P G K V P K P C C

210 220 230 240 250  
CGTGCCACCGAGCTGTCCGCCATCAGCATGCTGTACCTGGACGAGAATT  
V P T E L S A I S M L Y L D E N

260 270 280 290 300  
CCACCGTGCTGCTGAAGAACTACCAGGAGATGACCGTGGTGGGCTGCGGC  
S T V V L K N Y Q E M T V V G C G

310  
TGCCGCTAACTGCAG  
C R \*

16 / 19



SDS GEL ELUTION OF OSTEOGENIC ACTIVITY  
CALCIUM CONTENT (ug/mg tissue)

FIG. 14

## ALKALINE PHOSPHATASE (U/mg protein)



RAT MATRIX

BOVINE MATRIX

DEGLY. BOVINE MATRIX

FIG. 18

17 / 19




FIG. 16A




FIG. 16B




FIG. 17A




FIG. 17 B




FIG. 17C




FIG. 19A




FIG. 19B



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |  |   |  |
|--|--|---|--|
| (51) International patent Classification 4:<br>C07K 13/00, A61L 27/00, C12N 15/00<br>A61K 35/32, C12P 21/02  |  | A3  | (11) International Publication Number: <b>WO 89/09787</b><br>(43) International Publication Date: 19 October 1989 (19.10.89) |
| (21) International Application Number: PCT/US89/01453<br>(22) International Filing Date: 7 April 1989 (07.04.89)<br>(30) Priority data:<br>179,406 8 April 1988 (08.04.88) US<br>232,630 15 August 1988 (15.08.88) US<br>315,342 23 February 1989 (23.02.89) US<br>(60) Parent Applications or Grants<br>(63) Related by Continuation<br>US 179,406 (CIP)<br>Filed on 8 April 1988 (08.04.88)<br>US 232,630 (CIP)<br>Filed on 15 August 1988 (15.08.88)<br>US 315,342 (CIP)<br>Filed on 23 February 1989 (23.02.89)<br>(71) Applicant (for all designated States except US): CREATIVE BIOMOLECULES, INC. [US/US]; 35 South Street, Hopkinton, MA 01748 (US).<br>(72) Inventors; and<br>(75) Inventors/Applicants (for US only): KUBERASAMPATH, Thangavel [IN/US]; 6 Spring Street, Medway, MA 02053 (US). OPPERMANN, Hermann [US/US]; 25 Summer Hill Road, Medway, MA 02053 (US). RUEGER, David, C. [US/US]; |  | 150 Edgemere Road, Apt. 4, West Roxbury, MA 02132 (US). OZKAYNAK, Engin [TR/US]; 44 Purdue Drive, Milford, MA 01757 (US).<br>(74) Agent: PITCHER, Edmund, R.; Lahive & Cockfield, 60 State Street, Boston, MA 02109 (US).<br>(81) Designated States: AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CF (OAPI patent), CG (OAPI patent), CH (European patent), CM (OAPI patent), DE (European patent), DK, FI, FR (European patent), GA (OAPI patent), GB (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL (European patent), NO, RO, SD, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US.<br><br>Published<br>With international search report.<br>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.<br>(88) Date of publication of the international search report: 8 February 1990 (08.02.90) |  |
| (54) Title: OSTEOGENIC DEVICES   |  |   |  |
| (57) Abstract<br><br>Disclosed are 1) osteogenic devices comprising a matrix containing osteogenic protein and methods of inducing endochondral bone growth in mammals using the devices; 2) amino acid sequence data, amino acid composition, solubility properties, structural features, homologies and various other data characterizing osteogenic proteins, and 3) methods of producing osteogenic proteins using recombinant DNA technology.   |  |   |  |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                              |    |  |    |                          |
|----|------------------------------|----|--|----|--------------------------|
| AT | Austria                      | ES | Spain                                    | MG | Madagascar               |
| AU | Australia                    | FI | Finland                                  | ML | Mali                     |
| BB | Barbados                     | FR | France                                   | MR | Mauritania               |
| BE | Belgium                      | GA | Gabon                                    | MW | Malawi                   |
| BF | Burkina Faso                 | GB | United Kingdom                           | NL | Netherlands              |
| BG | Bulgaria                     | HU | Hungary                                  | NO | Norway                   |
| BJ | Benin                        | IT | Italy                                    | RO | Romania                  |
| BR | Brazil                       | JP | Japan                                    | SD | Sudan                    |
| CA | Canada                       | KP | Democratic People's Republic<br>of Korea | SE | Sweden                   |
| CF | Central African Republic     | KR | Republic of Korea                        | SN | Senegal                  |
| CG | Congo                        | LI | Liechtenstein                            | SU | Soviet Union             |
| CH | Switzerland                  | LK | Sri Lanka                                | TD | Chad                     |
| CM | Cameroon                     | LU | Luxembourg                               | TG | Togo                     |
| DE | Germany, Federal Republic of | MC | Monaco                                   | US | United States of America |
| DK | Denmark                      |    |  |    |                          |

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 89/01453

|  |   |   |
|--|---|---|
| <b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) *<br>According to International Patent Classification (IPC) or to both National Classification and IPC<br>IPC <sup>4</sup> : C 07 K 13/00, A 61 L 27/00, C 12 N 15/00, A 61 K 35/32,<br>C 12 P 21/02  |   |   |
| <b>II. FIELDS SEARCHED</b>   |   |   |
| Minimum Documentation Searched <sup>7</sup>  |   |   |
| Classification System  | Classification Symbols  |   |
| IPC <sup>4</sup>   | C 07 K, C 12 N, A 61 K, A 61 L, C 12 P  |   |
| Documentation Searched other than Minimum Documentation<br>to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>  |   |   |
|  |   |   |
| <b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>  |   |   |
| Category <sup>9</sup>  | Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>  | Relevant to Claim No. <sup>13</sup>                 |
| X,Y  | WO, A, 88/00205 (GENETICS INSTITUTE)<br>14 January 1988<br>see pages 1-12, 15-17, 22-24, 49;<br>pages 61-73, claims 1-23<br>--  | 1-16, 25,<br>26, 28, 32,<br>33                      |
| Y  | The Journal of Cell Biology, volume 97,<br>December 1983, The Rockefeller<br>University Press,<br>S.M. Seyedin et al.: "In vitro<br>induction of cartilage-specific<br>macromolecules by a bone extract",<br>pages 1950-1953<br>see the whole article, especially<br>page 1952, right-hand column<br>-- | 1-16, 25,<br>26, 28, 32,<br>33                      |
| Y  | EP, A, 0182483 (COLLAGEN CORP.)<br>28 May 1986<br>see the whole document, especially<br>page 6, first paragraph; page 7,<br>lines 10-18<br>--<br>./.  | 1-16, 25,<br>26, 28, 32,<br>33                      |
| <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 50%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div> |   |   |
| <b>IV. CERTIFICATION</b>   |   |   |
| Date of the Actual Completion of the International Search  |   | Date of Mailing of this International Search Report |
| 13th November 1989   |   | 10. 01. 90  |
| International Searching Authority  |   | Signature of Authorized Officer                     |
| EUROPEAN PATENT OFFICE   |   | T.K. WILLIS   |



| III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET) |  |                      |
|--|--|----------------------|
| Category *   | Citation of Document, with indication, where appropriate, of the relevant passages   | Relevant to Claim No |
| Y  | WO, A, 85/05274 (R.F. OLIVERS)<br>5 December 1985<br>see the whole document<br>--  | 8                    |
| Y  | Analytical Biochemistry, volume 146,<br>1985, Academic press, Inc.,<br>C.A. Olson et al.: "Deglycosylation<br>of chondroitin sulfate proteoglycan<br>by hydrogen fluoride in pyridine",<br>pages 232-237<br>see "Discussion" on page 236<br>--   | 8                    |
| A  | Trends in Biochem. Sci. (TIBS), volume 9,<br>1984, Elsevier Science Publishers B.V.,<br>(Amsterdam, NL),<br>E. Simpson: "Growth factors which<br>affect bone", pages 527-530<br>see the whole article<br>--  | 1-19,23-33           |
| A  | EP, A, 0148155 (DOW CHEMICAL CO.)<br>10 July 1985<br>cited in the application<br>--  |                      |
| A  | WO, A, 86/00526 (A.I. CAPLAN)<br>30 January 1986<br>--   |                      |
| A  | US, A, 4394370 (S.R. JEFFERIES)<br>19 July 1983<br>--  |                      |
| A  | US, A, 4563489 (M.R. URIST)<br>7 January 1986<br>--  |                      |
| A  | S.P. Colowick et al.: "Methods in<br>Enzymology", volume 146, Peptide<br>Growth Factors, part A, edited by<br>David Barnes et al., Academic Press<br>Inc.,<br>M.R. Urist et al.: "Preparation and<br>bioassay of bone morphogenetic protein<br>and polypeptide fragments", pages 294-<br>312<br>-- |                      |
| A  | EP, A, 0169016 (COLLAGEN CORP.)<br>22 January 1986<br>-----  |                      |

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers ..... because they relate to subject matter not required to be searched by this Authority, namely:

\*\* Claim numbers 20-22:

See PCT Rule 39.1(iv)

Methods for treatment of the human or animal body  
by surgery or therapy, as well as diagnostic methods.

2. ☒ Claim numbers ..... because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

\*\* Claim numbers 1-16, 19, 32, 33

See Article 6 PCT, 17(2)(a)(ii) PCT

./.

3. ☐ Claim numbers ..... because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This International Searching Authority found multiple inventions in this international application as follows:

Please see Form PCT/ISA/206 dated 14-8-89

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☒ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210 (supplemental sheet (2))

The present application is admittedly NOT the first to describe the phenomenon of bone inducing proteins, or devices containing them. It is therefore necessarily drafted to the individual compounds (on well-known devices).

In claims 1-16, however, proteins (on a device) are claimed, which are only defined by their biological activity and/or their molecular weight, which is clearly not sufficient for a full characterization of individual compounds. Despite this broad scope, the biological activity has only been demonstrated for one single compound (BOP 30K, which is covered by subject 1).

The search has therefore been restricted to the embodiments of claims 1-19 and 23-33, in as far as the proteins (and DNAs) correspond to the definitions given in the claims 17, 18, and 23-31.

This searchable subject matter has been regrouped according to the non-unity specification, in order to establish conceptually individual subjects, each of which now constitutes a potential selection invention.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

US 8901453  
SA 28156

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 19/12/89. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---------------------|----------------------------|---------------------|
| WO-A- 8800205                             | 14-01-88            | AU-A- 7783587              | 29-01-88            |
|   |                     | EP-A- 0313578              | 03-05-89            |
| EP-A- 0182483                             | 28-05-86            | US-A- 4563350              | 07-01-86            |
|   |                     | AU-B- 585268               | 15-06-89            |
|   |                     | AU-A- 4900585              | 01-05-86            |
|   |                     | JP-A- 62016421             | 24-01-87            |
| WO-A- 8505274                             | 05-12-85            | AU-B- 575660               | 04-08-88            |
|   |                     | AU-A- 4405285              | 13-12-85            |
|   |                     | CA-A- 1261760              | 26-09-89            |
|   |                     | EP-A- 0182842              | 04-06-86            |
|   |                     | JP-T- 61502588             | 13-11-86            |
| EP-A- 0148155                             | 10-07-85            | AU-B- 580975               | 09-02-89            |
|   |                     | AU-A- 3722184              | 11-07-85            |
|   |                     | CA-A- 1241641              | 06-09-88            |
|   |                     | JP-A- 60226814             | 12-11-85            |
|   |                     | US-A- 4804744              | 14-02-89            |
| WO-A- 8600526                             | 30-01-86            | US-A- 4620327              | 04-11-86            |
|   |                     | AU-A- 4601485              | 10-02-86            |
|   |                     | EP-A- 0188552              | 30-07-86            |
| US-A- 4394370                             | 19-07-83            | US-A- 4472840              | 25-09-84            |
| US-A- 4563489                             | 07-01-86            | None                       |                     |
| EP-A- 0169016                             | 22-01-86            | AU-A- 4501585              | 23-01-86            |
|   |                     | CA-A- 1261549              | 26-09-89            |
|   |                     | JP-A- 61036223             | 20-02-86            |
|   |                     | US-A- 4774322              | 27-09-88            |
|   |                     | US-A- 4774228              | 27-09-88            |
|   |                     | US-A- 4810691              | 07-03-89            |
|   |                     | US-A- 4843063              | 27-06-89            |



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |           |   |
|--|-----------|---|
| <b>(51) International patent Classification 4:</b><br>C07K 13/00, A61L 27/00, C12N 15/00<br>A61K 35/32, C12P 21/02   | <b>A3</b> | <b>(11) International Publication Number:</b> WO 89/09787<br><b>(43) International Publication Date:</b> 19 October 1989 (19.10.89)   |
| <b>(21) International Application Number:</b> PCT/US89/01453<br><b>(22) International Filing Date:</b> 7 April 1989 (07.04.89)<br><b>(30) Priority data:</b><br>179,406 8 April 1988 (08.04.88) US<br>232,630 15 August 1988 (15.08.88) US<br>315,342 23 February 1989 (23.02.89) US<br><b>(60) Parent Applications or Grants</b><br><b>(63) Related by Continuation</b><br>US 179,406 (CIP)<br>Filed on 8 April 1988 (08.04.88)<br>US 232,630 (CIP)<br>Filed on 15 August 1988 (15.08.88)<br>US 315,342 (CIP)<br>Filed on 23 February 1989 (23.02.89)<br><b>(71) Applicant (for all designated States except US):</b> CREATIVE BIOMOLECULES, INC. [US/US]; 35 South Street, Hopkinton, MA 01748 (US).<br><b>(72) Inventors; and</b><br><b>(75) Inventors/Applicants (for US only):</b> KUBERASAMPATH, Thangavel [IN/US]; 6 Spring Street, Medway, MA 02053 (US). OPPERMANN, Hermann [US/US]; 25 Summer Hill Road, Medway, MA 02053 (US). RUEGER, David, C. [US/US]; |           | 150 Edgemere Road, Apt. 4, West Roxbury, MA 02132 (US). OZKAYNAK, Engin [TR/US]; 44 Purdue Drive, Milford, MA 01757 (US).<br><b>(74) Agent:</b> PITCHER, Edmund, R.; Lahive & Cockfield, 60 State Street, Boston, MA 02109 (US).<br><b>(81) Designated States:</b> AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CF (OAPI patent), CG (OAPI patent), CH (European patent), CM (OAPI patent), DE (European patent), DK, FI, FR (European patent), GA (OAPI patent), GB (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL (European patent), NO, RO, SD, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US.<br><b>Published</b><br><i>With international search report.</i><br><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i><br><b>(88) Date of publication of the international search report:</b> 8 February 1990 (08.02.90) |
| <b>(54) Title:</b> OSTEOGENIC DEVICES<br><br><b>(57) Abstract</b><br><br>Disclosed are 1) osteogenic devices comprising a matrix containing osteogenic protein and methods of inducing endochondral bone growth in mammals using the devices; 2) amino acid sequence data, amino acid composition, solubility properties, structural features, homologies and various other data characterizing osteogenic proteins, and 3) methods of producing osteogenic proteins using recombinant DNA technology.   |           |   |

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                              |    |  |    |                          |
|----|------------------------------|----|--|----|--------------------------|
| AT | Austria                      | ES | Spain                                    | MG | Madagascar               |
| AU | Australia                    | FI | Finland                                  | ML | Mali                     |
| BB | Barbados                     | FR | France                                   | MR | Mauritania               |
| BE | Belgium                      | GA | Gabon                                    | MW | Malawi                   |
| BF | Burkina Faso                 | GB | United Kingdom                           | NL | Netherlands              |
| BG | Bulgaria                     | HU | Hungary                                  | NO | Norway                   |
| BJ | Benin                        | IT | Italy                                    | RO | Romania                  |
| BR | Brazil                       | JP | Japan                                    | SD | Sudan                    |
| CA | Canada                       | KP | Democratic People's Republic<br>of Korea | SE | Sweden                   |
| CF | Central African Republic     | KR | Republic of Korea                        | SN | Senegal                  |
| CG | Congo                        | LI | Liechtenstein                            | SU | Soviet Union             |
| CH | Switzerland                  | LK | Sri Lanka                                | TD | Chad                     |
| CM | Cameroon                     | LU | Luxembourg                               | TG | Togo                     |
| DE | Germany, Federal Republic of | MC | Monaco                                   | US | United States of America |
| DK | Denmark                      |    |  |    |                          |

# INTERNATIONAL SEARCH REPORT

International Application No PCT/US 89/01453

|  |   |   |
|--|---|---|
| <b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) *<br>According to International Patent Classification (IPC) or to both National Classification and IPC<br>IPC <sup>4</sup> : C 07 K 13/00, A 61 L 27/00, C 12 N 15/00, A 61 K 35/32,<br>C 12 P 21/02  |   |   |
| <b>II. FIELDS SEARCHED</b>   |   |   |
| Minimum Documentation Searched 7   |   |   |
| Classification System  | Classification Symbols  |   |
| IPC <sup>4</sup>   | C 07 K, C 12 N, A 61 K, A 61 L, C 12 P  |   |
| Documentation Searched other than Minimum Documentation<br>to the extent that such Documents are included in the Fields Searched *   |   |   |
|  |   |   |
| <b>III. DOCUMENTS CONSIDERED TO BE RELEVANT*</b>   |   |   |
| Category *   | Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>  | Relevant to Claim No. <sup>13</sup>                 |
| X, Y   | WO, A, 88/00205 (GENETICS INSTITUTE)<br>14 January 1988<br>see pages 1-12, 15-17, 22-24, 49;<br>pages 61-73, claims 1-23<br>--  | 1-16, 25,<br>26, 28, 32,<br>33                      |
| Y  | The Journal of Cell Biology, volume 97.<br>December 1983, The Rockefeller<br>University Press,<br>S.M. Seyedin et al.: "In vitro<br>induction of cartilage-specific<br>macromolecules by a bone extract",<br>pages 1950-1953<br>see the whole article, especially<br>page 1952, right-hand column<br>-- | 1-16, 25,<br>26, 28, 32,<br>33                      |
| Y  | EP, A, 0182483 (COLLAGEN CORP.)<br>28 May 1986<br>see the whole document, especially<br>page 6, first paragraph; page 7,<br>lines 10-18.<br>--<br>./.   | 1-16, 25,<br>26, 28, 32,<br>33                      |
| <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div> |   |   |
| <b>IV. CERTIFICATION</b>   |   |   |
| Date of the Actual Completion of the International Search  |   | Date of Mailing of this International Search Report |
| 13th November 1989   |   | 10. 01. 90  |
| International Searching Authority  |   | Signature of Authorized Officer                     |
| EUROPEAN PATENT OFFICE   |   | T.K. WILLIS   |

## III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

| Category * | Citation of Document, with indication, where appropriate, of the relevant passages   | Relevant to Claim No |
|------------|--|----------------------|
| Y          | WO, A, 85/05274 (R.F. OLIVERS)<br>5 December 1985<br>see the whole document<br>--  | 8                    |
| Y          | Analytical Biochemistry, volume 146,<br>1985, Academic press, Inc.,<br>C.A. Olson et al.: "Deglycosylation<br>of chondroitin sulfate proteoglycan<br>by hydrogen fluoride in pyridine",<br>pages 232-237<br>see "Discussion" on page 236<br>--   | 8                    |
| A          | Trends in Biochem. Sci. (TIBS), volume 9,<br>1984, Elsevier Science Publishers B.V.,<br>(Amsterdam, NL),<br>E. Simpson: "Growth factors which<br>affect bone", pages 527-530<br>see the whole article<br>--  | 1-19,23-33           |
| A          | EP, A, 0148155 (DOW CHEMICAL CO.)<br>10 July 1985<br>cited in the application<br>--  |                      |
| A          | WO, A, 86/00526 (A.I. CAPLAN)<br>30 January 1986<br>--   |                      |
| A          | US, A, 4394370 (S.R. JEFFERIES)<br>19 July 1983<br>--  |                      |
| A          | US, A, 4563489 (M.R. URIST)<br>7 January 1986<br>--  |                      |
| A          | S.P. Colowick et al.: "Methods in<br>Enzymology", volume 146, Peptide<br>Growth Factors, part A, edited by<br>David Barnes et al., Academic Press<br>Inc.,<br>M.R. Urist et al.: "Preparation and<br>bioassay of bone morphogenetic protein<br>and polypeptide fragments", pages 294-<br>312<br>-- |                      |
| A          | EP, A, 0169016 (COLLAGEN CORP.)<br>22 January 1986<br>-----  |                      |



FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE :

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers \*\* because they relate to subject matter not required to be searched by this Authority, namely:

\*\* Claim numbers 20-22:  
See PCT Rule 39.1(iv)  
Methods for treatment of the human or animal body  
by surgery or therapy, as well as diagnostic methods.

2. ☒ Claim numbers \*\* because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

\*\* Claim numbers 1-16, 19, 32, 33  
See Article 6 PCT, 17(2)(a)(ii) PCT

./.

3. ☐ Claim numbers ....., because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING :

This International Searching Authority found multiple inventions in this international application as follows:

Please see Form PCT/ISA/206 dated 14-8-89

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

☒ The additional search fees were accompanied by applicant's protest.

☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/210 (supplemental sheet (2))

The present application is admittedly NOT the first to describe the phenomenon of bone inducing proteins, or devices containing them. It is therefore necessarily drafted to the individual compounds (on well-known devices).

In claims 1-16, however, proteins (on a device) are claimed, which are only defined by their biological activity and/or their molecular weight, which is clearly not sufficient for a full characterization of individual compounds. Despite this broad scope, the biological activity has only been demonstrated for one single compound (BOP 30K, which is covered by subject 1).

The search has therefore been restricted to the embodiments of claims 1-19 and 23-33, in as far as the proteins (and DNAs) correspond to the definitions given in the claims 17, 18, and 23-31.

This searchable subject matter has been regrouped according to the non-unity specification, in order to establish conceptually individual subjects, each of which now constitutes a potential selection invention.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

US 8901453  
SA 28156

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 19/12/89. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s)   | Publication<br>date  |
|---|---------------------|--|--|
| WO-A- 8800205                             | 14-01-88            | AU-A- 7783587<br>EP-A- 0313578   | 29-01-88<br>03-05-89   |
| EP-A- 0182483                             | 28-05-86            | US-A- 4563350<br>AU-B- 585268<br>AU-A- 4900585<br>JP-A- 62016421   | 07-01-86<br>15-06-89<br>01-05-86<br>24-01-87                                     |
| WO-A- 8505274                             | 05-12-85            | AU-B- 575660<br>AU-A- 4405285<br>CA-A- 1261760<br>EP-A- 0182842<br>JP-T- 61502588                                    | 04-08-88<br>13-12-85<br>26-09-89<br>04-06-86<br>13-11-86                         |
| EP-A- 0148155                             | 10-07-85            | AU-B- 580975<br>AU-A- 3722184<br>CA-A- 1241641<br>JP-A- 60226814<br>US-A- 4804744                                    | 09-02-89<br>11-07-85<br>06-09-88<br>12-11-85<br>14-02-89                         |
| WO-A- 8600526                             | 30-01-86            | US-A- 4620327<br>AU-A- 4601485<br>EP-A- 0188552  | 04-11-86<br>10-02-86<br>30-07-86   |
| US-A- 4394370                             | 19-07-83            | US-A- 4472840  | 25-09-84   |
| US-A- 4563489                             | 07-01-86            | None   |  |
| EP-A- 0169016                             | 22-01-86            | AU-A- 4501585<br>CA-A- 1261549<br>JP-A- 61036223<br>US-A- 4774322<br>US-A- 4774228<br>US-A- 4810691<br>US-A- 4843063 | 23-01-86<br>26-09-89<br>20-02-86<br>27-09-88<br>27-09-88<br>07-03-89<br>27-06-89 |

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☒ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**